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ABSTRACT 
The research route of this PhD started from workplace drug testing, an emerging need for 
safety and hygiene at work. The aim of the work consisted of developing and validating 
analytical methods: innovative tools for drug addiction monitoring and for illicit drugs 
testing.  
 
Different classes of psychotropic substances are examined in relation to their chemical and 
pharmacological effects, with a special focus on new psychoactive substances (NPS) and 
new trends of abuse. The most important biological matrices, suitable for analysis, are 
studied and the peculiarities of each matrix are highlighted. Analytical methods were 
developed for drugs determination in biological samples, such as human urine, plasma, oral 
fluids and hair. All these matrices are equally important for forensic purposes as they give 
different kind of information about the time of assumption and they show some distinctive 
features. Sample preparation is a critical step and is a key factor in determining the success 
of analysis: the task of chemist is to develop the best strategy to ensure that the system, 
consisting of 3 variables,  matrix - target analytes - instrumental equipment, will be solved 
consistently with the ultimate purpose of the analysis. Therefore in this project appropriate 
sample preparation techniques have been investigated with special regard to each different 
matrix. The manual operations associated with these processes are often expensive, labor-
intensive and time-consuming and affect the uncertainty of the final analytical data, for these 
reasons in this work new procedures based on innovative sample preparation were 
investigated and developed. The goal has been to provide short sample preparation times, 
automation of the clean-up step and low sample volumes, minimizing the consumption of 
solvents and chemicals. 
Development of methods based on liquid chromatography coupled with tandem mass 
spectrometry (LC–MS/MS) was a crucial component of this work. LC–MS is considered to 
be the benchmark for quantitative/qualitative bioanalysis, providing specificity, sensitivity 
and speed to the method. Different chromatographic conditions have been evaluated for the 
optimal separation and detection of the investigated compounds. As a new trend, the 
application of columns with superficially porous packing materials has been investigated, 
which allowed fast chromatographic runs and high efficiency. 
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The versatility of the LC-MS/MS has been proven by providing a single analytical method 
for the determination of 11 drugs of abuse in biological fluids: conventional matrices, such 
as plasma and urine, and unconventional ones, such as oral fluids. 
 
The research route was then directed to hair analysis and for the first time pressurised liquid 
extraction (PLE) was shown to be effective for the extraction of drugs belonging to different 
classes from hair samples. Experiments were carried out to ensure correct interpretation of 
the analytical data by studying the phenomenon of external contamination (a critical point in 
the analysis of hair for forensic purposes).  
To improve the methods selectivity, multi reaction monitoring (MRM) acquisition modes 
were used for quantification of the investigated compounds in both cases. 
 
Finally analytical target was extended to NPS: a method for the screening of 
methylenedioxyamphetamine and piperazine-derived compounds in urine was developed. 
These substances, characterized by possessing common moieties, are screened using 
precursor ion and neutral loss scan mode and then quantified in MRM acquisition mode. 
 
All the methods developed have been validated according to specific international guidelines 
to ensure reliable results, unambiguously interpreted and useful for forensic purposes. 
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INTRODUCTION 
The abuse of alcohol and drugs is a social problem discussed for some time, but the analysis 
of the consequences in the field of safety and hygiene at work is relatively recent. The 
implications of the continued abuse of illicit drugs (see also box 1.0) in the workplace 
represents a high cost to society. Vittadini and Lanfranco analyzed alcoholism and drug 
addiction in the workplace: it is reported that alcohol and drugs would be responsible for 
even 47% of accidents occurred [1]. Hence the need of appropriate analytical tools for 
effective drug testing and monitoring, as also highlighted in the Mandatory Guidelines for 
Federal Workplace Drug Testing guidelines of SAMSHA [2]. 
Illicit drugs testing in biological matrices encompasses a variety of procedures, that range 
from general unknown analysis for a wide variety of drugs and screening procedures for 
well-defined drug classes to the specific confirmation and quantification of individual 
compounds.  
Screening of drugs is usually achieved by means of immunoassays; enzyme immunoassays 
(EIA and EMIT), enzyme linked immunoassays (ELISA) and fluorescence-polarization 
immunoassays (FPIA) are the most diffused. However, in the last years screening tests are 
often performed with techniques reserved in the past only to confirmation procedure (for 
quantitative purposes), i.e. liquid chromatography (LC) and gas chromatography (GC) 
coupled with mass spectrometry (MS) capabilities [3, 4]. In fact, after screening and 
identification, the relevant analytes must be quantified; according to SOFT-AAFS guidelines 
[5] all quantification assays must be performed by GC–MS(MS) or LC–MS/MS and they 
have to be fully validated. Confirmation procedures may involve the targeted analysis of 
well-defined drug classes or multi-analytes approaches. In this respect LC–MS and 
especially LC–MS/MS is increasingly used avoiding the expensive and time consuming 
derivatization step that is required for the analysis of a number of drugs, especially 
metabolites, in GC–MS. 
The core of the PhD project has been the development of novel analytical method with 
special regards to innovative techniques for sample preparation. Both single-class and multi-
analytes quantification methods have been developed by LC–MS/MS in the most important 
biological matrices. The analytes taken into account belong to different classes, namely 
opiates, cocainics, amphetamines, cannabinoids and hallucinogens which are discussed in 
§1, a focus box on novel psychotropic substances (NPS) closes the topic. Biological matrices 
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and their specific features are treated in §2 and guidelines for the development of an 
analytical method are briefly mentioned in §3. Sample preparation techniques, i.e. solid 
phase extraction (SPE), liquid liquid extraction (LLE) and protein precipitation (PP) are 
discussed in §4. 
The experimental work has been divided in three sections, following the research route; 
section I is reserved to determination of illicit drugs in biological fluids using µ-SPE for 
sample pretreatment; in section II extraction of drugs from hair by pressurised liquid 
extraction (PLE) is investigated; section  III is dedicated to screening method for 
identification of new methylenedioxyamphetamine- and piperazine-derived designer drugs. 
 
1. Target compounds 
1.1 Opiates 
Opiates are derived from opium, a naturally occurring product obtained from the plant 
Papaver somniferum. The major psychoactive components of opium are morphine, codeine 
and thebaine. Diacetylmorphine (heroin) has been synthetically derived from morphine and 
is the most commonly opiate sold in the illicit market. This substance has an extremely short 
half-life (about 5 minutes) and it is rapidly metabolized to 6-monoacetylmorphine (6-MAM) 
and further to morphine. Morphine is then largely metabolized by conjugation to morphine-
3β- and 6β-glucuronides (Figure 1). While the former metabolite is inactive, the latter shows 
an analgesic activity even greater than the parent compound [6]. 
Other misused opiates include dihydrocodeine and codeine, which is available in over-the-
counter preparations but can also be found in street heroin, together with 6-acetylcodeine. 
Detection of heroin’s metabolite, 6-MAM, is important from a forensic point of view since it 
allows the differentiation between heroin and morphine or codeine consumption because 
heroin itself is rarely found in any conventional biological matrix. However since 6-MAM 
half-life is of about 40 minutes it is detectable in urine at maximum for 8 hours after heroin 
assumption [7]. For this reason the cut-off value of 6-MAM in urine is very low, i.e. 10 ng 
mL
-1
. This metabolite is more likely to be detected in oral fluid (OF), blood and hair. In hair 
care should be taken to prevent analyte hydrolysis during extraction. 
Opiates have a wide range of pharmacological effects: analgesia, sedation, respiratory 
depression, decreased gut motility, and cough depression. They are clinically used in the 
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relief of moderate to severe pain and as cough sedatives; they are abused for their complex 
psychotropic effects producing tolerance and physical dependence. 
 
Synthetic opiates, such as fentanyl, buprenorphine and methadone are also becoming 
important; they are not necessarily structurally related to morphine but they show agonistic 
effect at the same receptors, producing similar psychoactive effects; they are often used in 
the treatments of heroin dependence [8]. 
Testing urine for heroin and morphine usually begins with hydrolysis of the conjugates to 
liberate free morphine prior to sample clean-up and chromatography; hydrolysis can be 
performed either enzymatically or by addition of strong acids. The performance of different 
kind of enzymes and of acid hydrolysis on the cleavage of morphine conjugates was tested 
by Zezulak et al. and Lin et al., acid hydrolysis resulted always more effective. Direct 
analysis of conjugates is also possible by LC often coupled with MS(/MS) [9] and has been 
stimulated by the recognition of the role of morphine 6β-glucuronide (M-6G) as an active 
metabolite. In fatal cases the ratio of morphine to its glucuronides has been shown to be a 
useful tool to determine survival time between ingestion and death [7]. In plasma morphine 
glucuronides levels exceed those of morphine 0.5 hours after dosing and remain higher at all 
times thereafter [10].  
Figure 1. Metabolic pathway of diacetylmorphine (heroin) 
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Very often opiates determination is included in multi-class methods together with all the 
most common drugs of abuse like cocaine and metabolites, amphetamines, benzodiazepines 
etc [11]. 
1.2 Cocaine 
The primary source of cocaine is the Erythroxylum coca plant that grows abundantly on the 
eastern slopes of the Andes Mountains in Peru and Bolivia where as early as 3000 years ago 
coca leaves were chewed primarily to enhance physical performance and to decrease the 
need for food and rest. Illicit cocaine use grew slowly for many years, and then increased at 
a rapid pace in the 1970s; today is the second most used illicit drug after cannabis due to its 
powerful addictive stimulant action [12]. 
In humans, cocaine (COC) is extensively metabolized by both enzymatic and nonenzymatic 
pathways. Its primary metabolites include benzoylecgonine (BZE) and ecgonine methyl ester 
(EME) while other metabolites such as the active norcocaine (NCOC) and 
benzoylnorecgonine (BNE) are usually detected at considerably lower concentrations. 
Cocaethylene (CE) is another metabolite that may serve as biomarker for co-ingestion of 
alcohol because the transesterification of COC to CE is faster than hydrolysis to BZE in the 
presence of ethanol. The cocaine metabolites are excreted in urine usually for 36–48 hours, 
so the presence of cocaine metabolites in this matrix indicates recent drug use [13]. The main 
metabolites are shown in Figure 2.  
The amount of parent drug and its metabolites varies notably depending on the selected 
biological matrix. In hair and oral fluids (over the first 4 h) cocaine is more concentrated 
than its metabolites which are more polar and so less liable to passive diffusion compared to 
the parent drug [14], in urine cocaine is often not detectable so BZE and EME are markers of 
its consumption. In plasma BZE is the primary detected metabolite while EME is generally 
detected only at low concentrations following cocaine administration by the intranasal, 
intravenous and smoked routes [15] however, following controlled oral administration, EME 
was present in plasma at concentrations up to four times that of cocaine. Also NCOC was 
found to be present at substantial concentrations following oral administration [16]. 
The analysis of cocaine in biological specimens may be complicated by its instability 
particularly in blood which contains cholinesterase, while BZE and EME are more stable; in 
hair testing time-consuming “soft digestion” are preferred to prevent any conversion of 
cocaine to BZE. 
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1.3 Amphetamines 
Amphetamine and methamphetamine are powerful stimulants of the central nervous system 
by acting as indirect sympathomimetic drugs which have been in use since the early 1900s. 
These drugs have a single asymmetric centre and therefore they exist as two enantiomers, 
each of which has different pharmacological activities [17].  
Over the years, several substitutions have been made to the parent molecules to modify their 
activity. A group of related drugs, often referred to as ‘designer amphetamines’, includes 
several methylenedioxy analogues which are often found on the illicit market as an abused 
drug. These compounds include 3,4-methylenedioxyamphetamine (MDA), 3,4-
methylenedioxymethamphetamine (MDMA) or “ecstasy” and 3,4-
methylenedioxyethylamphetamine (MDEA). The structures of amphetamine, 
methamphetamine, MDA, MDMA and MDEA are shown in Figure 3.  
The analysis of amphetamine, methamphetamine and related parent compounds requires no 
hydrolysis since they do not undergo to conjugation; the main metabolic pathway involves 
aromatic and aliphatic hydroxylation, N-demethylation and oxidative deamination [18]. 
Analysis of the phenolic metabolites, that are partly excreted as conjugates, does require 
Figure 2. Metabolic pathway of cocaine 
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hydrolysis which is typically accomplished using either acid or enzymatic procedures but in 
most methods, only the parent compounds are analyzed. 
 
Amphetamine-derived designer drugs undergo predominantly two overlapping metabolic 
pathways: O-demethylenation to dihydroxy derivatives (catechols) followed by methylation 
of one of the hydroxy groups, and further degradation of the side chain to N-dealkyl and 
deaminooxo metabolites [18]. MDA, MDMA, and MDE are additionally metabolized to 
glycine conjugates of the corresponding 3,4-disubstituted benzoic acids, so-called hippuric 
acid derivatives. Their half-lives are shorter compared to amphetamine and 
methamphetamine. 
Amphetamines are basic drugs, therefore their excretion is strongly influenced by urine pH 
and their excretion profile is not easily predictable being amphetamines half-lives very 
variable; for instance if the pH of the urine is neutral, approximately 30% of the ingested 
amphetamine is eliminated unchanged, but if the pH is 5, up to 74% is eliminated unchanged 
[19]. Analysis of enantiomer composition can, in some cases, provide significant additional 
information for interpretation. The S(+) enantiomer is the most active form of amphetamine 
and methamphetamine [20]. In fact there is ample evidence, that the two enantiomers are 
metabolized at substantially different rates being the S(+) enantiomer metabolized more 
rapidly than the R(-) enantiomer. For this reason, the proportion of the S(+) to the R(-) 
Figure 3. Amphetamines structures 
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enantiomer changes with time and can be helpful in the determination of how long since the 
drug was taken [17]. 
Concentrations of amphetamines in OF are usually higher than in blood and so they can 
easily be detected, also in small volumes of sample; amphetamines can be detected for 20 to 
50 hours with detection limits of 10 ng mL
-1
 [19]. Similarly in hair, concentrations are high 
and a good within-subject correlation between dose and methamphetamine and amphetamine 
hair concentrations was reported by Polettini et al. [21]. Amphetamines are generally stable 
to strong basic and acid conditions, so alkaline digestion or acid extraction are the most 
diffused method for their extraction from hair. 
 
BOX 1.0 Spot on Law Enforcement action against illicit drugs diffusion 
 
This box provides an overview of psycotropyc substances intercepted by a territorial branch 
of the Forensic Police Service of Central Anti-Crime Directorate of National State Police 
(Department of Public Safety – Ministry of Interior), the Interregional Forensic Police Office 
(GIPS) of Ancona. The data shown in Tables B1.1 and B1.2 are not involved with an 
epidemiological study on the consumption of psychotropic substances, but they are a 
warning on the continued spread and abuse of those illicit drugs, which already represents 
for years a high social cost. 
It should be underlined that the GIPS has exclusive competence for the investigations carried 
out by the State Police and often gives also scientific support to Financial Police in their 
investigations, while the scientific support for the investigations carried out by Carabinieri is 
guaranteed by their own specialized units. 
Analysis of illicit drugs is performed by GIPS only in criminal proceedings (and not in 
administrative ones) on express request of the competent court. This activity of forensic 
support reflects the priorities of the investigative offices which in turn reflect the territorial 
peculiarities. So from Fermo and Ascoli P. judicial authorities will require more probably 
analysis of street drugs, ready for the end users  (psychoactive substance diluted with cutting 
agents); instead from Ancona, requests most likely will concern large quantities of marijuana 
and/or heroine, due to the presence of the port connected with the area over-Adriatic sea; in 
these cases, psychoactive substances are more concentrated, these will be stored for later 
distribution throughout the national territory or only for transit; greater criminal organization 
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will be probably involved. These concepts are found in the tables below, in particular on the 
percentage of marijuana (Table B1.1) and the average percentage of diacetylmorphine (Table 
B1.2) in the data referred to Ancona. 
Table B1.2 it also show the low significance of amphetamine-type substances and even less 
for the so-called NPS (see box 2) than other illicit drugs. The legitimate question is: the 
spread and abuse of these substances is reflected in this data (albeit geographically restricted 
and with the limitations described above) or there is the need to do more and better both 
from the point of investigation both from point of forensic analysis to have full cognizance 
of the phenomenon? 
 
 
Table B1.1. Overview of drugs of abuse detected by GIPS of Ancona related to the 
different cities (data expressed as a percentage). Reference periods 2013-2014. 
 
 
 
 
Table B1.2. Average percentage of psychoactive substance found in the samples 
analyzed by GIPS of Ancona in the period 2013-2014. In Marijuana and Hashish 
psychoactive substance quantified was THC. 
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1.4 Cannabinoids 
Cannabinoids are a group of compounds unique to the plant Cannabis sativa L.. This plant 
has been known since centuries not only for medical purposes, but also as a “recreative” 
drug, widely consumed among young and adults in the last fifty years. Nowadays it is the 
most used illicit drug in the world [12]. Three cannabis preparations are illicitly trafficked: 
herbal cannabis (marijuana), cannabis resin with fine plant particles (hashish), and cannabis 
extract (cannabis oil or hash oil). 
The psychotropic effects of this plant, are due to Δ9-tetrahydrocannabinol (THC) which 
together with cannabinol (CBN) and cannabidiol (CBD), is the main representative of a 
group of about 70 terpenophenolic compounds, collectively known as phytocannabinoids 
[22]. THC is rapidly absorbed, passes into the blood stream and, due to its lipophilicity, can 
spread throughout the body and penetrate the brain, interacting with the molecular targets, 
called cannabinoid receptors (CBR) [23, 24].
 
Cannabinoids are rapidly and extensively metabolized by hepatic enzymes [25, 26]. The 
major pathway involves hydroxylation to 11-hydroxy-THC (THC-OH), a psychoactive 
metabolite, followed by further oxidation to inactive 11-nor- Δ9-tetrahydrocannabinol-9-
carboxylic acid (THC-COOH). THC and its metabolites subsequently undergo phase II 
biotransformation to glucuronide conjugates. THC and its hydroxylated metabolites are 
conjugated through ether bonds; THC-COOH metabolite forms this ether bond as well, but 
predominately forms an ester bond between the glucuronide and carboxyl moiety [27] 
(Figure 4). 
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Figure 4. Metabolic pathway of THC and structure of main cannabinoids. 
 
The usual target compounds in blood samples are THC and its major metabolites, THC-
COOH and THC-OH). Some methods also detect THC-COOH-glucuronide [28], since this 
metabolite has been suggested as a marker of a recent cannabis use [29].  
Cannabinoids analysis in hair is not straightforward because of the low concentrations of 
THC and of its major metabolite THC-COOH, its acidic properties not favouring 
incorporation into the cortex of the hair strand (fg mg
-1
) [30-32]. Despite the low 
concentrations in hair samples, the determination of THC-COOH has been shown to be 
crucial to distinguish between passive drug exposure and active consumption since this 
metabolite is formed exclusively within the body. 
In urine the target analyte for cannabinoids analysis is THC-COOH which is primarily 
excreted as its glucuronic conjugate. The detection windows can be very large: about four 
days in occasional smokers [33] and up to months for chronic users [13]. THC and THC-
OH, excreted as well in the form of glucuronides, may be present in lower concentrations. A 
procedure of hydrolysis is generally performed before analysis to convert the conjugated 
drugs in their free form. Cleavage of the glucuronic bond can be accomplished by basic or 
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enzymatic hydrolysis. However the basic hydrolysis is not sufficient to deconjugate the 
glucuronide of THC and THC-OH [34]. The direct analysis of THC conjugates can also be 
performed by LC–MS/MS [35-39]. 
In OF, THC and THC-COOH have been shown to remain longer that other drugs of abuse, 
up to 22 h; CBD and CBN can instead be used as marker of recent cannabis use [40]. High 
concentrations in OF primarily arise from oral mucosal contamination during smoking and 
minimal partitioning into blood is observed; OF/P ratio is variable over time, generally high 
ratios (>10) are found within a few hours and afterwards a decrease is observed [41]. 
Very often cannabinoids are not included in multi-class methods, since their lipophilic nature 
involve specific sample preparation. Their analysis is complicated by the possible absorption 
on laboratory vessels and by their low concentrations in biological samples. 
 
1.5 Hallucinogens 
Typically, a hallucinogen causes the user to have a heightened state of awareness of sensory 
input (audio, visual, etc.) and diminished control over the experience. 
Hallucinogens are usually plant alkaloids or derivatives and can be divided into several 
categories. In this work we just focused on ketamine, mescaline, phencyclidine (PCP), 
psilocybin and psilocin (Figure 5).  
All these drugs have been included in several multi-analyte detection methods [42-45]. 
Mescaline is a naturally occurring alkaloid found in the peyote cactus Lophophora williamsii 
but it is also synthesized for illicit use.  
Psilocybin is a naturally occurring compound found in mushrooms of the genus Psilocybe 
commonly referred to as “magic mushrooms”. The drug is typically ingested by eating the 
mushrooms. In addition to psilocybin, the mushroom also contains small amounts of psilocin 
which is nearly twice as potent as psilocybin. It has been shown that in human psilocybin 
showed rapid dephosphorylation to psilocin which is primarily excreted as the glucuronide 
conjugate rather than the free compound [46, 47]. Enzymatic hydrolysis with β-
glucuronidase from E. coli has been shown to be optimal for conjugates hydrolysis [48]; in 
acid conditions the analytes are not stable while with basic hydrolysis no cleavage is 
observed. 
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PCP and ketamine are classified as anesthetics and were initially developed for that purpose; 
they have the same arylcyclo-alkylamine skeleton and are capable of producing some 
hallucination effects. Plasma, serum and urine are the most widely used biological fluids for 
PCP. Typically, only the parent drug is analyzed, however the parent drug is rapidly and 
extensively metabolized within the body and only small concentrations are detectable in 
urine and plasma; hair is for this reason a valuable specimen [49]. 
Ketamine is often used in drug facilitated crimes [50], it has relatively short distribution and 
elimination half-life; its major metabolite is nor-ketamine, which, together with the parent 
compound can be detected in the different biological matrices [51]. 
 
 
 
 
  
 
 
  
Figure 5. Chemical structures of some hallucinogens 
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BOX 2.0  
Focus on Novel Psychotropic Substances   
 
This box provides an overview of the so-called Novel Psycotropic Substances (NPS). The 
first part discusses the phenomenon of global dissemination, while the second part shows the 
chemical classification of substances with some examples represented in Figure B2.1 
 
NPS: worldwide diffusion and Italian “silent tsunami” 
Since the late 1990s and early 2000s there has been an explosion in clandestinely produced 
designer drugs of abuse that have considerably changed the illicit drug market. Whereas in 
earlier decades drug abuse was restricted to a clear number of substances, in the last years 
more than 100 new designer drugs of abuse have been introduced. The continuous search for 
and synthesis of designer drugs and their widespread consumption result in a growing 
number of reports about seizures, abuse and intoxication. The term “new (or novel) 
psychotropic substances” (NPS) relates to psychotropic substances that are either 
synthetically changed natural compounds, modified molecular structures of existing drugs or 
completely different, designed, chemicals; the term ‘new(or novel)’ means that these drugs 
have recently appeared on the illicit drug market and that they are newly abused, it does not 
necessarily mean that they have been synthesized or discovered recently.  
Over the last century an extensive survey of structural variations has been conducted by 
pharmaceutical companies, universities and other researchers from which some new designer 
drugs have been derived. Sometimes these drugs can be regarded as ‘failed pharmaceutical 
agents’ that already have been described in scientific literature but did not find their way to 
legal medical use (e.g., benzylpiperazine [BZP] or synthetic cannabinoids)[52]. 
Due to the legal situation in many countries, which try to ban drugs or to regulate their use 
by scheduling them, producers and users are looking for ways to bypass illegality. As 
substances usually have to be structurally defined to be scheduled, minor structural changes 
of common drugs are sufficient to outsmart the official law, at least for some time. Novel 
substances can appear directly in response to legislative action to replace a similar recently 
banned drug.  
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) coordinates 
information exchange and creates risk assessments for single substances that are basis for 
national legal acts. EMCDDA was created in 1997 and reinforced in 2005, after the 
underestimation of the phenomenon of MDMA diffusion. An early warning system (EWS) 
21 
 
was created and it reports on newly encountered psychoactive substances facilitating the 
sharing and disseminating of information among EU member states. Griffith has recently 
identified in synthetic opioid the class of substances that currently represents the latest 
warning in Europe (in Romania they replaced heroin)[53]. EMCDDA studies underlined that 
NPS, because of the greater pharmacological effectiveness (i.e. 5 grams of 25I-NBOMe, a 
derivative of phenethylamine, are sufficient for 10000 doses), are imported / distributed at 
lower concentrations then classical drug of abuse, so it is required a greater sensitivity in 
detection systems. In England and Ireland NPS abuse has actually already exceeded that of 
traditional drugs of abuse, furthermore the abuse of NPS in Northern Europe is clearly 
established [53, 54].  
A system similar to European EWS exists in the USA to monitor nationwide diffusion of 
NPS. O’Brien, recently showed that two SCN were among the 10 most detected drugs of 
abuse in USA already in 2012 (namely two synthetic cannabinoids: XLR-11 and AM-
2201)[55]. United Nations Office on Drugs and Crime (UNODC) publish annually the 
World Drug Report, a document reporting a detailed overview of recent world drug trends, 
trafficking routes and regional consumption patterns and gives statistics about production, 
seizures, prices, consumption and treatment. Gerra, member of UNODC, about NPS 
phenomenon recently underlined these points [56]: 
 in some countries, mephedrone is replacing heroin (without overcoming the intake by 
injection and the possible hazards derived); 
 in Australia there is a growing abuse of ketamine; 
 an increasingly important share of consumers consists of teenagers; 
 in USA there is a worrying abuse of NPS among military forces; 
 the NPS were increasingly widely used as adulterants of traditional drugs of abuse. 
Global widespread access to the internet is an important supporting factor. The internet is a 
big marketplace for designer drugs because it facilitates distribution of information, 
networking, ordering chemicals and selling drugs worldwide. Often, new designer drugs are 
marketed as ‘legal highs’ or ‘research chemicals.’ 
 This new illicit market, revealed by Central  Directorate of Anti-drug Services of the 
Department of Public Safety-Ministry of Interior, can be outlined as follows. 
1. Order online from websites. 
2. Payment by credit card / bit-coin / paypal (but also payment on delivery) 
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3. Shipping is from packaging and storage sites distributed across Europe. Substances 
stored there were purchased from chemical industries (actually mostly detected in 
China). 
4. Delivery within 48 hours. 
In this context data on the diffusion in Italy of NPS abuse are collected by the Department 
for Antidrug Policies-Presidency of the Council of Ministers (DPA), which instituted the 
National Early Warning System (NEWS) similar to European EWS. 
87 synthetic cannabinoids, 42 synthetic cathinones, 67 phenethylamines, 5 piperazine, 8 
tryptamines, 4 ketamine-related compounds are a part of the NPS intercepted in Italy from 
2009 to 2013 by NEWS. In contrast to new therapeutic drugs whose metabolism and toxicity 
are usually thoroughly investigated before application in patients, no systematic risk 
assessment is performed for new designer drugs. Consequently, it is impossible to predict 
possible drug–drug interactions, interindividual variations in metabolic profiles, side effects 
and serious poisonings. At best, limited experiences from self experiments can be found in 
books such as PIHKAL [57], TIHKAL [58] and internet forums. Lacking dosage finding 
studies, quality controls and exactly weighed dosages, it is not surprising that the abuse of 
new designer drugs has led to several intoxications with both nonfatal and fatal outcomes in 
the last years [52].  
NEWS registered in Italy about 600 cases of acute intoxication (35% caused by ketamine 
and related compounds, and 23% from SCN): 40% of people aged up to 25 years and a 
significant 60% of people aged over 25 [56]. The pattern of nationwide distribution of these 
cases is strongly inhomogeneous with some accentuated diffusion gradients, such as the area 
of the Triveneto. Serpelloni called the phenomenon in Italy a “silent tsunami” because of the 
lack of attention by media. The National Action Plan of the DPA for NPS provides a 
network of collaborating centers tightly interlaced with each other through the management 
structure of the NEWS. There are two specialist areas in NEWS, one for analytical and bio-
toxicological aspects (National Institute of Health) and one for clinical-toxicological aspects 
(Poison Control Center of Pavia) [54]. 
The role of the chemical laboratory and the analytical identification of NPS is empathized in 
this National Action Plan. Laboratory must have suitable analytical tools dedicated to 
determination of NPS, which is essential for the sequels of competence (i.e. diagnosis, 
medical treatment, monitoring of the abuse or for eventual criminal or administrative 
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proceedings). In fact, action of the DPA provided for the upgrading of law enforcement 
laboratories throughout the country[54].  
 
 
NPS: chemical classification [52] 
 
Phenylalkylamines. The basic structures of amphetamine and 3,4-methylenedioxy-N-
methylamphetamine (MDMA) have been the starting point for a lot of modifications that 
were made mainly at the aromatic system, less frequently at the amine function and the alkyl 
chain. The generated derivatives on the basis of their substituents can be divided into smaller 
subgroups: dimethoxyphenylpropanamines (i.e DOB), dimethoxyphenylethanamines (so-
colled 2C family), Trimethoxy derivates, β-keto-compounds (i.e. mephedrone), 
methylenedioxyamphetamine-derived (i.e. MDPA), ecc.  
Tryptamines. Tryptamine is the basic structure of hallucinogenic psilocybin, the 
psychoactive ingredient in ‘magic mushrooms’ and bufotenin, another naturally occurring 
psychoactive alkaloid. Designer drugs with tryptamine structure have an effect because of 
their similarity to serotonin. 
 
Piperazines. Next to the phenylalkylamines, the representatives of the piperazine group 
have gained most significance, as can be seen in the scientific literature, which is full of 
analytical methods, case reports and papers that deal with analytical profiling of confiscated 
or purchased substances. Structurally the piperazines can again be divided in two subgroups: 
BZPs and phenylpiperazines. Since the beginning of the 21st century BZP and 3-
trifluoromethylphenylpiperazine (TFMPP) have been circulating among drug consumers, 
sometimes in a combination that is said to have ecstasy-like effects but rather resembles to 
an amphetamine–mescaline mixture. Later, mCPP, MDBP and MeOPP appeared and other 
derivatives followed. The piperazine derivatives act as stimulants (e.g., amphetamine) and 
can also produce euphoria. Additionally, TFMPP and mCPP have small hallucinogenic 
potential that may be led back to an interaction of 1-aryl-piperazines with serotonin 
receptors. 
Phenylcyclohexyl derivates.These compounds are structurally derived from phencyclidine 
(PCP) and probably act as NMDA channel blockers, as does PCP. 
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Synthetic cannabinoids. A large variety of compounds divided in 4 subgrpoups: ‘classical 
cannabinoids’, which are ∆9-THC analogues like HU-210;  cyclohexylphenols , a result of 
research of Pfizer, such as CP 497,47-C8, which was discovered in the most famous herbal 
blend ‘Spice’; so-called JWH compounds, a large series of naphthoylindoles and 
naphthoylpyrroles and other naphthalin-containing structures like JWH-018 and JWH-073; 
Eicosanoids that resemble endogenous cannabinoids, as well as other species that do not 
share any structural characteristic with the three other groups.   
 
Pyrrolidinophenones are structurally related to cathinone and the β-keto compounds, but 
differ from those in the pyrrolidine heterocyclic ring system that embeds the nitrogen atom 
of the amine function. 
 
Figure B2.1 Chemical structures of some NPS. Structures of some 
phenylalkylamines: β-keto compounds and methylenedioxyamphetamine 
- derived (top). Structures of some piperazines: benzylpiperazines and 
phenylpiperazines (bottom) 
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2. Biological matrices 
Biological samples are extremely complex matrices, containing many components that can 
interfere with chromatographic separations and/or mass spectrometer response; sample 
preparation is thus an important aspect of bioanalytical estimation. 
Biological matrices can be divided into two groups, i.e. conventional and alternative 
matrices. In forensic analytical chemistry, analysis is typically conducted on fluids such as 
urine, serum and plasma which thus are conventional matrices. Besides these, alternative 
matrices such as oral fluid, hair, sweat or meconium have become important. 
All these matrices are equally important for forensic purposes as they give different kind of 
information about the time of assumption and they show some distinctive features. In 
general, the detection time is longest in hair, followed by urine, oral fluid, and blood (Figure 
6.). 
 
 
Figure 6. Median time windows of drugs in the most important biological matrices. 
 
2.1 Blood, plasma and serum 
Blood is the transporter of many vital substances and nutrients for the entire body (an adult 
has a blood volume of about 5 L), thus it contains many endogenous and exogenous 
compounds in a wide range of concentrations.. Whole blood (WB) consists mostly of water 
but also contains dissolved proteins, mineral ions, glucose, hormones, platelets and cells. 
The physiological pH is maintained at 7.4 by a complex buffer system and a minimal change 
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produces serious health consequences. The variation of physiological parameters within 
narrow limits makes blood an advantageous testing-matrix.  
Plasma is the liquid part of blood which is prepared by spinning fresh blood containing an 
anticoagulant. Like WB it contains dissolved proteins which can lead to protein binding of 
the analytes and may be detrimental for the separation and detection. 
Serum is the liquid fraction of WB and it is collected after the blood is allowed to clot; it has 
the same composition of plasma but it is deprived of fibrinogen and other clotting factors. 
Most drugs are not equally distributed between the subcompartments of blood, it depends on 
the affinity of drugs for erythrocytes; consequently, the concentration in serum or plasma 
may differ from that in whole blood. Whole blood/plasma ratio (WB/P) typically vary 
between 0.5 to 1.2 for most drugs of abuse [59]. 
Determination of illicit drugs in WB, plasma and serum is of great importance in forensic 
toxicology because the substances can be detected just after the exposure, prior to 
metabolism. For this reason detection of drugs in blood can be very useful to evaluate the 
degree of impairment. Among the tested matrices blood presents the shorter time windows; 
drugs of abuse can be detected at the low nanogram per milliliter level for 1 or 2 days. 
However the detection time is influenced by many factors: the dose, the preparation and 
route of administration, acute versus chronic use, the nature of the molecule [19]. For 
example, the detection window for heroin is very short, amphetamines are detectable for 
about 48 hours in plasma while THC-COOH, the main metabolite of THC has an half-life of 
2-5 days and can be detected during a period of 12 days in chronic users [19]. 
Drug determination in human plasma is not straightforward because of the high protein 
content which can lead to protein binding of the analyte, and is complicated by the low 
concentrations that are often found (0.1 – 10 ng mL-1 level). An extra problem posed by 
blood testing is the low sample volume that is normally available. 
 
2.2 Urine 
Compared with blood, urine is relatively free of protein, thus making it possible for direct 
extraction; simple dilution and even direct injection after centrifugation [60] are possible 
avoiding long sample preparation procedures.  
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Urine contains high concentrations of metabolites and provides for most drugs a longer 
detection time compared to blood, from several days for opiates and cocaine, up to months 
for chronic cannabinoid use. Urine is the matrix of choice for monitoring drug exposure in 
workplace testing and for screening and identification of unknown drugs also because their 
concentrations are relatively high. In addition its collection is physically non-invasive and it 
is often available in large volumes. 
Limitations of urine drug testing are well known adulteration tactics, the pH variability that 
can affect the excretion pattern of certain drugs (amphetamines for example) and the low 
concentration or even lack of the parent drug [61]. In this case metabolites, which often 
consist of conjugates with glucuronic acid or sulphate must be detected. Another limitation 
of urine is that the amount of drugs are not well correlated with drug concentrations at the 
effector sites and with impairment. The presence of drug in urine is only a marker of 
previous use, and this does not necessarily mean that the person is under the influence; even 
though roadside drug screening is still performed using urine sample, the results are often of 
no legal usefulness. 
Most drug conjugates are highly hydrophilic and not amenable to normally performed 
extraction methods. Thus, pretreatment procedures generally include gentle enzymatic 
hydrolysis or fast acid hydrolysis of such metabolites; alkaline hydrolysis is only suitable for 
cleavage of conjugates with an ester bond like THC-COOH glucuronide. Compared to 
enzymatic cleavage, acid and basic hydrolysis are less time consuming and cheaper, however 
not all the analytes are stable under the strong conditions required. 
 
2.3 Oral fluid 
Oral fluid is a composite of a number of fluids (including saliva) secreted into the oral cavity 
primarily by three glands: the parotid, submaxillary, and sublingual glands, as well as by 
other smaller glands. Limitations in oral fluid testing are its variable viscosity, pH and flow 
depending on a range of physiological variables. In addition external contamination (i.e. 
positivity does not arise from active drug consumption but rather from passive exposure) can 
be an issue; in these cases detection of metabolites can be crucial. 
The transport mechanism of drug from blood to oral fluid is largely by passive diffusion 
particularly of unionized drug in blood plasma that is not bound to proteins [62]. Oral fluid 
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predominantly contains the parent drug because of its higher liposolubility that favours 
passive diffusion. For the same reason, drugs with high liposolubility tend to have higher 
concentrations. The concentration of drug in oral fluid is also dependent on the respective 
pH of the two fluids and the pKa of the drug in question. Basic drugs which are usually 
unionized at salivary pH (6.2-7.4) have a relatively high concentration in oral fluid compared 
to drugs with a low pKa.  
Detection windows of drugs in OF (5-48 h) is similar to blood. OF testing has gained 
increased attention in the last years, especially in driving under the influence of drugs 
(DUID) investigations, first of all because it can be obtained easily by non-medical 
personnel in a non-invasive and observable way and also because for most drugs there is a 
good correlation with plasma concentration and with degree of impairment. In practice the 
OF/blood concentration ratio is not constant and for some drugs, especially THC, absorption 
in the mucosa of oral cavity results in poor correlation; THC has been shown to be detected 
in OF for up to 22 hours [40], long after a person might be adversely affected by the drug.  
A common way to collect OF is the insertion in the mouth of a sorbent material on and 
around the tongue similar to a cotton bud. The device is placed in the mouth for a few 
minutes until sufficient fluid has been absorbed. This is then added to a diluent (aqueous 
buffered solution) that dilutes the OF and makes it more amenable to analysis but may be 
inconvenient if analytes are in very low concentrations. Furthermore most devices have been 
reported to have a significant effect on drug concentration found in OF [63, 64]: one of the 
potential pitfalls related to the use of absorbent swabs is that there may be some loss of drug 
on the swab itself. Expectoration or passive drool may be preferred in this respect, because, 
in addition to the lower costs, they better reflect real drug concentrations in excreted saliva 
[65]. However, some drugs have been reported to have lower stability in expectorated OF 
compared to OF collected with devices (Quantisal) [66]; in addition samples are often 
viscous and can be contaminated with food and other debris.  
 
2.4 Hair 
Hair is mainly composed of protein (65–95%, essentially keratin), water, lipids, and 
minerals. The hair shaft consists of an outer cuticle that surrounds a cortex; it originates from 
a follicle which is surrounded by a rich capillary system that provides the growing hair with 
necessary metabolic material. The growth of hair occurs in cycles, alternating between 
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periods of growth (anagen phase) and periods of quiescence (catagen and telogen phases). 
Head hair is produced at a rate of approximately 0.6–1.42 cm.month-1 [67]. Pubic hair, arm 
hair, and axillary hair are possible alternative sources for drug detection when scalp hair is 
not available; however, the data interpretation in these cases is more complex. 
The precise mechanism by which chemicals are incorporated in hair is still unclear, but it is 
generally considered that xenobiotics can enter hair by at least three mechanisms: passive 
diffusion from blood capillaries into growing hair cells, deposition by diffusion from sweat 
or sebum secretions into the completed hair shaft, and from the external environment [68]. 
According to the passive diffusion model, excretion of drugs in hair should be delayed a few 
days because new hair takes some time to emerge from the skin surface and be available for 
shaving [21]. The chemical properties of the incorporated substance as well as the 
physical/physiological characteristics of the individual strongly influence which mechanism 
will dominate. Three key factors influence the drug incorporation. These include the melanin 
content of hair and the lipophilicity and basicity of the substance itself: pigmented hair will 
contain higher drug amount and similarly to OF, lipophilic and basic drugs will be more 
concentrated.  
In abusers most drugs are expected to be found in the nanogram per milligram range; 
cannabinoids are usually found at lower concentrations (pg mg
-1
) and THC-COOH is even 
less concentrated. In the last years it has been shown that single drug exposure is detectable 
in hair for most drugs, concentrations in the low picogram per milligram are expected [69, 
70]. 
Hair differs from other materials used for toxicological analysis because of its unique ability 
to serve as a long-term storage of foreign substances, due to its large detection window 
which is weeks to months depending on the length of the analysed hair shaft. Other 
advantages are that it is easy to collect, store and transport. Moreover, segmental analysis of 
hair strands allows the determination of the historic pattern of drug use. Consequently, hair 
analysis of illicit drugs and medicines is currently employed to address a wide range of 
challenges, such as drug abuse history, workplace testing, post-mortem toxicology, 
therapeutic drug monitoring or drug facilitated assault (DFA) investigations [71]. In DFA 
cases, single exposure must be detected and hair is of particular value, because the crimes 
are often reported long time after any drugs have been eliminated from blood or urine.  
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The most crucial issue facing hair analysis is the avoidance of false-positive results caused 
by passive exposure to the drug. For this reason SoHT recommends that hair analysis starts 
with a wash step to remove external contamination [71]. Following this step hair is generally 
incubated in solvent medium where drugs are transferred and then extracted. Only the 
detection of drug metabolite(s) in hair establishes that internal drug exposure has occurred, 
verifying the positivity of the sample. 
Extraction of drugs from hair is usually performed by enzymatic or alkaline digestion with 
concentrated NaOH (only possible when the analytes are stable under the required strong 
conditions), by methanol extraction which is compatible with almost all drug classes but is 
often incomplete, longer and gives dirt extracts or by aqueous acids or buffer extraction [68].  
3. LC-MS Analysis 
The toxicological analysis is essential in the clinical and medico-legal process, being aimed 
at seeking evidence of the presence of psychoactive substances in biological fluids and 
tissues. The fields of intervention of a clinical toxicology laboratory are mainly two: 
 clinical toxicology, where the analysis are made with a therapeutic purpose; 
 forensic toxicology, which performs analysis for administrative and forensic 
purposes.  
Since errors in analytical forensic toxicology may lead to legal consequences for both the 
offender and the injured, obtain a meaningful and reliable analytical data is mandatory.  
LC–MS or LC-MS/MS has helped this field closing the gap with respect to hydrophilic, 
thermolabile and non-volatile analytes that were not sufficiently covered by the established 
gold standard technique (GC–MS) [72]. Jenkins et al. compared with each other LC-MS, 
LC-UV and GC-MS determination of the specific case of MDMA showing how the coupling 
LC-MS technique is very versatile, sensitive and selective analysis of drugs of abuse and 
pretreatment is relatively simple [73]. LC-MS and LC-MS/MS are thus largely replacing 
GC-MS and GC-MS/MS in the analysis of drugs of abuse, because it does not require 
derivatization, is capable of simultaneous determination of both conjugated drugs of abuse 
that free forms in a single analysis without the intermediate step of hydrolysis pretreatment 
of the sample: these are important advantages in terms of analysis time and performance 
[74]. 
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3.1 Development of an analytical method: guidelines 
Specific guidelines or procedures have been adopted in order to assist the chemist and 
directing him towards the practical applications, for which a new analytical method is being 
created, including measures of verification and external assessment. In 1996 the American 
Board of Forensic Toxicology launched the Forensic Toxicology Accreditation Program 
based on the guidelines of the Society of Forensic Toxicologists in American Academy of 
Forensic Sciences (SOFT/AAFS): the final document was adopted and the latest version was 
published in 2006 [75]. In Europe there is a document relating to the performance of 
analytical methods and interpretation of results aimed to identification of drug residues in 
foodstuffs, which is sometimes used: the regulation 2002/657/EC [76]. The German 
guidelines of the Society of Toxicological and Forensic Chemistry (GTFCh) are, instead, of 
a more exquisitely forensic. In 2006 a document entitled "Drugs of Abuse Testing 
Guidelines" was published by AGSA (Swiss Working Group for Drugs of Abuse Testing 
Guidelines) and supported by the major public institutions in Switzerland. However, there 
are also those issued by the Food and Drugs Administration (FDA) relating bio-analytical 
method [77], sometimes supplemented with EMEA’s homologue document [78] and SOFT-
AAFS or 2002/657/EC [76]. SOFT-AAFS guidelines also assist and guide the laboratory on 
the procedure to be followed before chemical analysis: from sampling to acceptance of 
sample, rules to be followed to ensure traceability: documentation that proves adequate chain 
of custody, without which the following analytical results would be unusable in a court.  
All guidelines specify that in the case of analysis aimed at medico-legal purposes, the 
analytical steps envisaged are basically two: the screening tests and the confirmatory tests. 
Screening tests allow to quickly analyze several samples, even by untrained personnel, in 
an economic, efficient and standardized to prevent a negative samples: these ones identify 
samples in which the concentration is below a threshold value defined cut-off (a reference 
value, expressed in concentration, above which the result of an analytical test is considered 
positive and below which the test is considered negative). These methods, therefore, should 
aim to limit the error of false negative below a certain threshold. 
3.2 Validation 
Validation involves documenting, through the use of specific laboratory investigations, that 
the performance characteristics of the method are suitable and reliable for the intended 
analytical applications. The acceptability of analytical data is related to the criteria used for 
the validation. Reliable analytical data are a prerequisite for correct interpretation of 
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toxicological findings in the evaluation of scientific studies, as well as in daily routine work. 
Unreliable analytical data might not only be contested in court, but could also lead to 
unjustified legal consequences for the defendant or to wrong treatment of the patient. 
Therefore, new analytical methods to be used in forensic and/or clinical toxicology require 
careful method development and thorough validation of the final method.  
The fundamental parameters for this validation include accuracy, precision, selectivity, 
sensitivity, reproducibility, and stability [77]. Other parameters are: limits of detection 
(LODs) and quantification (LOQs), linear dynamic range (LDR) [75]. In the case of LC-
MS/MS based procedures, appropriate steps should be taken to ensure the lack of matrix 
effects throughout the application of the method, as outlined by several authors [79-84] 
3.3 Quality management and accreditation 
Quality management and accreditation have become matters of increasing relevance in 
analytical toxicology in recent years. Forensic laboratory accreditation is based upon 
international standards (ISO/IEC 17025:2005 [85]) which include requirements for method 
validation and allows to control and monitor overtime the laboratory performance and its 
analysts by proficiency tests [86].  
4. Sample preparation and matrix effect 
To produce meaningful information, the analysis has to be performed on a representative 
sample of the material from which it was taken. Biological samples cannot normally be 
injected directly into the analysing system without sample preparation.  
Sample pretreatment is thus of utmost importance for the adequate analysis of drugs and it is 
performed to dissolve or dilute the analyte in a suitable solvent, removing the interfering 
compounds and pre-concentrating the analyte. However, this is a difficult step which takes 
50-75% of the total time of the analysis; conventional sample preparation involves PP and/or 
SPE and LLE. 
When LC–MS(/MS) is the selected technique for detection the main function of sample 
preparation is the reduction of matrix effect (ME) by removing co-eluting interfering 
compounds; in fact one limitation associated with LC–MS, especially using electrospray 
(ESI) ion source, is its susceptibility to ME. 
In this case ME is defined as the effect of co-eluting residual matrix components on the 
ionization of the target analyte. Typically, suppression or enhancement of analyte response is 
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accompanied by diminished precision and accuracy of subsequent measurements. ME thus 
limits the utility of LC–MS for quantitative analysis and is a major issue in method 
development. 
MEs usually interfere with the analyte response proportionally to analyte concentration, they 
occur through reactions or interactions between the analyte(s) and some matrix constituents 
resulting in species that can either suppress or rarely enhance signal response in the MS. Ion 
suppression in ESI has been explained by different mechanisms [87], these include: 
 competition between matrix components and analyte ions that are co-eluting in the 
sprayed solution for access to the droplet surface for gas-phase emission; 
 matrix interferences that compete for available charge; 
 co-precipitation of the analytes with non-volatile materials; 
 neutralization of analyte ions through gas phase acid/base reactions. 
Current validation guidelines for bioanalytical methods require the evaluation of ME as a 
part of method development; there are two common methods to assess MEs, i.e. the post-
column infusion and the post-extraction addition methods. The former, initially proposed by 
Bonfiglio et al. [88], method provides a qualitative assessment of MEs by the identification 
of regions in the chromatogram that are most subjected to suppression or enhancement. This 
is carried out by monitoring the signal of a constant infused solution of the analyte(s) into 
the eluent from the analytical column when a blank sample is injected, by a post-column tee 
connection. In the absence of matrix interferences the continuous post column infusion led to 
a constant signal in the detector, while elution of compounds that can enhance or suppress 
the analyte signal led to increased or decreased signal. In contrast, the post-extraction 
addition approach allows a quantitative assessment of the MEs by comparing the response of 
the analyte in a standard solution with the response of the analyte spiked into a blank matrix 
sample after all the extraction procedure. Generally MEs are assessed at different 
concentrations over the linear range (at least 2); an alternative approach to evaluate MEs 
over the entire range is to compare the slope of two calibration curves, one prepared in 
solvent and one in matrix (post-extraction). Peters et al. have highlighted in a recent review 
[89] the importance of assess the variability of ME (RSD%) using at least 6 different matrix 
sources and they suggest that the variability of MEs between samples is at least as important 
as the average extent of these effects. 
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Residual matrix components in biological materials which cause ion suppression are mainly 
endogenous phospholipids, sugars or salts, creatinine in urine, amino acids and proteins. 
Because phospholipids have been identified as a major source of MEs when dealing with 
biological materials, multiple researchers have shown the convenience of monitoring the 
levels of various phospholipids in the samples to assess the effectiveness of the clean-up. In 
fact it has been shown that even if phospholipids do not co-elute with drugs, their presence 
can result in retention time shifts, elevated baselines, and divergent curves, thus influencing 
assay performance [90]. Single phospholipids can be monitored [91] or alternatively in-
source collision induced dissociation (CID) with a high cone voltage and a low collision 
energy can be used to monitor the 184 and 104 ions only, which are characteristic of 
glycerophosphocholines (GPChos) and 2-lyso glycerophosphocholines (2-lyso GPChos) 
respectively, resulting in total ion chromatograms (TIC) representing all compounds 
containing the phosphocholine head group [92, 93]. 
Clearly large differences in the extent of matrix effects can be observed between different 
matrix types and between different sample preparation techniques, including direct injection, 
dilution, protein precipitation (PP), solid-phase extraction (SPE) and liquid–liquid extraction 
(LLE).  
The reduction of MEs can be obtained by changing chromatographic parameters so that the 
analyte does not fall into suppression zones, by the use of atmospheric pressure chemical 
ionization (APCI) instead of ESI which is less susceptible to matrix effect [94] or better by 
optimizing the sample preparation step. 
4.1 Protein precipitation 
PP is commonly used for fast sample clean-up in illicit drugs testing. This technique is based 
on the removal of proteins from the matrix by denaturing them directly in the initial sample, 
commonly by the addition of a water miscible organic solvent (e.g. methanol, ethanol, 
acetonitrile or acetone), a strong acid, such as trichloroacetic acid (TCA) and trifluoroacetic 
acid (TFA) or less frequently by means of salts and metal ions. The denatured proteins are 
then removed from the sample by centrifugation. The precipitant agent is often able to 
disrupt protein-drug binding, allowing drug direct determination. 
Precipitants exert specific effects on proteins to facilitate their precipitation from solution. 
Protein solubility in biological fluids results from polar interactions with the aqueous 
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solvent, ionic interactions with salts and repulsive electrostatic forces between equally 
charged molecules.  
Polson et al. [95], comparing different protein precipitation approaches, found that the most 
efficient protein precipitants for protein removal are zinc sulphate, acetonitrile and TCA 
when the ratio to plasma volume is 2:1 or greater; lower ion suppression is obtained with 
acidic precipitants since they extract less interfering compounds, however when dealing with 
lipophilic drugs, acidic precipitants result in lower recoveries. Often different protein 
precipitants such as zinc sulphate/methanol [96] can be combined to obtain optimal 
performances; in the specific case it has been shown that the use of the two combined 
precipitants provided samples with a content of phospholipids 2.5 times lower, compared to 
other precipitants. 
PP is commonly used for analysis of drugs of abuse in plasma/serum and OF [97], it is the 
fastest and simplest clean-up approach and is applicable for both hydrophilic and 
hydrophobic compounds, however it is not a very efficient technique due to its non-selective 
nature, in addition the analyte(s) may be adsorbed on the proteins, and a significant amount 
of un-precipitated plasma components may still remain. A number of authors, compared 
different sample preparation techniques and found that PPT is the least effective and causes 
significant ion suppression for many compounds [83, 91]. Very often PP is used prior to SPE 
to have cleaner extract. 
a. Ultrafiltration 
Ultrafiltration uses a membrane filter to separate the proteins from the sample. A centrifugal 
force is applied to accelerate the diffusion and, thus, the entire process. Low molecular 
weight compounds are able to pass through the filter, which has pores of a certain size range, 
while the proteins are retained on the filter. 
Ultrafiltration has been shown to be a suitable technique for clean-up applications since it 
allows the reduction of matrix effect with a minimal handling. Compared with classical PP, 
the clean-up appears more efficient in terms of matrix effect reduction and automation of the 
procedure [98]. 
b. Protein precipitation plates 
PP plates are membrane-based filter firstly developed by Biddlecombe et al. [99]. 
Structurally, these plates contain tubes with a membrane filter and are attachable to vacuum 
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filtration; after precipitation of protein, filtration can be carried out in the same well without 
centrifugation and supernatant transfer steps. Generally they are available in 96-well format, 
which enables both manual and robotic automation for the entire process. 
It has been shown, than compared to PP, use of PP plates leads to more reproducible results 
[100]. Moreover, significant reduction in the sample preparation time is obtained. 
This approach has recently been used for the rapid analysis of drugs belonging to different 
classes in OF [101]; high recoveries were obtained for all analytes however significant 
matrix effects were found for a number of drugs.  
4.2 Liquid liquid extraction 
LLE is a classical technique involving the partitioning of analytes between two immiscible 
liquids, based on the octanol-water partition coefficient. The choice of the extraction solvent 
is crucial, it should match the analytes polarity while still being immiscible with water and it 
should preferably be compatible with the detection method. Other factors, such as pH and 
ionic additives may greatly affect the extraction efficiency; extraction is performed at a pH 
value at which the analyte is not ionized.  
This technique is quite easy however some shortcomings: emulsion formation, use of large 
sample volumes and toxic organic solvents make LLE expensive, time-consuming and 
environmentally harmful. Another drawback of LLE is its unsuitability for hydrophilic 
compounds such as many drugs metabolites. In addition organic solvent do not provide a 
selective extraction and when dealing with complex matrices such as blood, LLE has the 
potential for increased matrix effects compared to SPE [91].  
Despite its disadvantages, LLE is still widely used in the sample preparation of biological 
fluids for the analysis of illicit drugs and can be convenient when a wide range of different 
analytes must be extracted [102]. 
a. Miniaturized techniques 
The miniaturization of LLE has led to the development of a number of new methodologies. 
Miniaturized LLE techniques use negligible volumes of extracting solvent and a minimum 
number of steps. 
Single-drop micro-extraction (SDME) is based on the use of a micro-drop (1-10 μL) of 
extraction solvent immiscible with the sample. In direct injection (DI)-SDME the micro-
drop is suspended in a stirred aqueous solution from the tip of a micro-syringe needle. After 
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extracting for a given period of time, the drop is retracted back into the micro-syringe needle 
and finally injected into the chromatographic system. Head space (HS)-SDME allows to 
work with more volatile analytes, the extraction is performed by exposing the solvent drop to 
the head-space above the sample. Another sub-category of SDME is constant-flow micro-
extraction (CFME) [103], in this case the extraction is carried out by a micro-syringe which 
is introduced in an extraction chamber where the sample is continuously pumped at a 
constant flow-rate. Due to the continuous contact with the flowing fresh sample solution, the 
extraction efficiency and concentration factor are higher than in static extraction [104]. 
Liquid-liquid-liquid micro-extraction (LLLME) is also based on a single drop extraction and 
is suitable for ionisable analytes. The analyte is firstly extracted into an organic layer which 
possesses a lower density than water and then back-extracted into an aqueous micro-drop. 
The pH of the aqueous solution and the aqueous micro-drop can be adjusted to obtain firstly 
the neutral form of the analyte, extractable by organic solvent and then ionize it to be 
extracted into aqueous drop [105]. 
In hollow fibre liquid phase micro-extraction (HF-LPME), analytes of interest are extracted 
from aqueous samples, through a thin layer of organic solvent immobilized within the pores 
of a porous hollow fibre, and into an acceptor solution inside the lumen of the hollow fibre 
[106]. The whole assembly is placed in a sample solution and the target analytes are 
extracted from the sample through a supported liquid membrane; the micro-extract is not in 
direct contact with the sample solution. As a result, samples may be stirred or vibrated 
vigorously without any loss of the micro-extract. Analyte enrichment factors are very high 
without the need for evaporation and reconstitution. 
Dispersive liquid-liquid micro-extraction (DLLME) is based on a ternary component solvent 
system in which an appropriate mixture of extraction solvent and disperser solvent is quickly 
injected into the aqueous sample with a syringe. The mixture is then gently shaken and a 
cloudy solution is formed; after centrifugation, the fine particles of extraction solvent are 
precipitated in the bottom of a conical test tube and collected with a syringe. The water-
immiscible extracting solvent should have a higher density than water, while the disperser 
solvent should be miscible in the extracting solvent and the aqueous sample, usually acetone, 
acetonitrile and methanol are used for this purpose [107]. The fine droplets of extraction 
solvent are dispersed throughout the aqueous sample, allowing interaction with the analyte. 
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All the cited LLME techniques are quite diffused in forensic toxicology for the extraction of 
multiple analytes from urine [108-113] and hair [114-117]. 
b. Pressurized liquid extraction 
Pressurized liquid extraction (PLE) or accelerated solvent extraction (ASE
®
) involves 
extraction with solvents at high pressure and temperature without reaching their critical 
point, so that they are kept in the liquid state. The use of high pressures allows employing 
solvents above their atmospheric boiling points to increase solvation power and extraction 
kinetics. The utilization of organic solvent can thus be reduced or even eliminated as the 
dramatic changes in the physical-chemical properties of water enhances its usefulness as an 
extraction solvent. 
PLE can be performed both in the static and dynamic modes; in the first mode sample and 
solvent are maintained for a defined time at constant temperature and pressure while in 
dynamic mode fresh solvent is continuously introduced to the sample improving the 
extraction but diluting the sample. Optimization of the extraction process generally begins 
with an appropriate choice of the extraction solvent. A single solvent, a mixture of solvents 
of different nature or solvents modified with additives such as surfactants can be used. PLE 
extraction is generally not selective thus resulting in the co-extraction of different matrix 
components, thus PLE eluent is generally submitted to a clean-up procedure. 
PLE has advantages over other extraction methods, including better reproducibility, the 
reduced use of extraction solvent, reduced time and automation of sample preparation [118]. 
PLE can be used exclusively with solid samples thus limiting its application in forensic 
toxicology where analysis are usually conducted on liquid matrices; applications in drug 
testing are limited to airborne particles [119] and wastewater particulate [120, 121]. In the 
present study PLE has been tested for the extraction of drugs from hair with excellent results 
[122]. 
c. Salting-out LLE (SALLE) 
The concept of salting-out is well-known, when an inorganic salt is added to a mixture of 
water and water-miscible solvent it leads to the separation of the solvent from the mixture, 
forming a biphasic system. Salting-out in bioanalysis using acetonitrile as organic solvent 
was firstly introduced by Rustum et al. [123]. The salt-induced phase separation between 
acetonitrile and aqueous solution may be induced by the addition of a variety of inorganic 
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and organic electrolytes, mainly magnesium, ammonium or calcium sulphate, sodium or 
calcium chloride but also ammonium acetate which is more “LC–MS friendly”. 
Overall, SALLE offers several advantages over conventional LLE such as applicability to a 
broad range of drugs from low to high lipophilicity, improved recoveries and analyte 
enrichment, availability of a range of salts, making it possible to comply efficiently with 
LC–MS/MS methods. A recent application of SALLE in forensic toxicology has regarded 
the extraction of synthetic cannabinoids metabolites from urine [124] 
 
4.3 Solid phase extraction 
SPE is the most popular sample pre-treatment approach in drug testing, its main advantages 
are: high recoveries, need for less organic solvent (compared to LLE), possibility of pre-
concentration, ease of operation and greater possibility of automation [118]. 
The technique involves passing a liquid sample through a solid sorbent bed, usually 
consisting of modified silica particles. The aim is to retain the analytes in the sorbent bed, 
wash away interferences and finally elute the analytes as a clean extract in a small volume. 
One advantage of SPE over LLE is that it requires lower amounts of organic solvents for the 
extraction, which is important for environmental and health reasons. SPE also often offers 
higher selectivity for the target compound(s) due to the wide range of sorbent types 
available. Other advantages of SPE are its higher enrichment factors and the possibility of 
automation. 
Different formats and SPE sorbents which provide various selectivity is available. The 
choice of sorbent phase is the key factor in SPE, by far the most widely used phase is 
chemically bonded silica C18 and less C8; in the last years polymer-based sorbents 
(polystyrene, divinylbenzene and many others) are more and more diffused, their advantages 
being stability over the entire pH range and higher surface areas. Ion exchange materials, 
grafitized carbon and mixed mode sorbent (containing both nonpolar and strong cation/anion 
exchange) are also quite diffused. Recently new sorbents based on increased selectivity, such 
as molecular imprinted polymers (MIPs) and aptamers (reviewed in the next paragraphs) 
have been introduced. 
The analyte can be retained on the sorbent surface by a range of different types of 
interaction, such as hydrogen bonds, dipole-dipole or dipole-induced dipole mechanisms, 
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dispersive, charge transfer or ionic interactions. The three main modes of SPE for organic 
compounds utilizing one or several of these interactions are: reversed-phase, normal-phase, 
and ion-exchange systems.  
In spite of all advantages stated above, SPE in some cases is time-consuming and relatively 
expensive, as SPE cartridges are manufactured for single use only. They sometimes have 
poor batch-to-batch reproducibility and still require a relatively large amount of organic 
solvent.  
 
a. Miniaturized techniques 
SPE devices are available in a variety of formats, and in the last years there has been 
increasing attention towards miniaturized devices. Miniaturized SPE offers the big 
advantage of reducing the volumes of sample and solvents used in the process, in addition 
new formats allow to minimize the manual operations associated with SPE reducing time 
required for extraction. 
µ-SPE or disposable pipette extraction (DPX) uses a standard pipette tip which contains a 
sorbent loosely packed between two frits. Being a pipette tip, is it easy to take the solvent in 
or out through this dispersive sorbent, without requiring vacuum neither for loading or 
elution, as it occurs in classic SPE. In addition using automatic pipettes several specimens 
can be processed simultaneously, improving laboratory throughput.  
The steps involved with µ-SPE are similar to those of SPE, but normally the sample is 
withdrawn/aspirated through the tip several times to obtain an effective extraction both in the 
loading and elution phase. Commercially tips are available with a variety of sorbents (C18, 
C8, anion and cation exchange) and capacity (200 µL to 5 ml). µ-SPE has been used in 
several fields, recent applications with drugs of abuse are found in the literature. A method 
for the analysis of several drugs of abuse in urine has been reported [125], while in other 
studies DPX was used for the extraction of opiates from vitreous humour [126] or THC and 
THC-COOH from blood and urine using 200 µL of sample [127]. µ-SPE has been also used 
by our research group for the extraction of a wide variety of drugs from OF [42] , plasma 
and urine [128] whose optimization has been part of the PhD project. 
Another new technique which is based on the miniaturization of SPE is micro-extraction on 
packed sorbent (MEPS) which has been firstly introduced by Abdel-Rehim et al. [129]. In 
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MEPS the sorbent bed is reduced to a few mg and inserted in the barrel of a syringe (100-
250 µL). The technique is designed for sample volumes ranging from 10 µL to 1000 µL and 
provide easy automation by directly insert the syringe in an autosampler. Similarly to µ-SPE, 
samples can be drawn and ejected several times to increase extraction efficiency and is also 
possible to work with a large volume, by aspiring multiple times from the same vial if pre-
concentration of the sample is required.  
MEPS protocol involves pre-treatment of complex samples such as dilution and 
centrifugation. Dilution with water followed by centrifugation is recommended for 
plasma/serum and whole blood samples. One of the most significant advantages of MEPS is 
that the same sorbent bed can be reused many times just by washing with water and an 
appropriate solvent; it has been reported that the same needle can be reused up to 120 times 
without any loss of performance [130]. All the sorbent normally found in SPE can be used 
with MEPS, included MIPs to obtain an increased selectivity [131, 132] . Recent 
applications of MEPS in forensic toxicology include the rapid screening of opiates [133] and 
cocaine [134] in urine. In the experimental part (section I) the optimisation of a method for 
the extraction of cannabinoids from OF using MEPS will be described [135]. 
Solid phase micro extraction (SPME) is the first miniaturized SPE technique, which has 
been introduced in the 1990 by Arthur and Pawliszyn [136]. Today is very diffused and used 
as frequently as the traditional preparation techniques. SPME devices consist of a modified 
syringe that contains a fused-silica fibre tip which is coated with an organic polymer within 
its syringe needle. In contrast to conventional SPE, SPME syringe assembly allows 
combination of all the steps of sample preparation into one step, thus reducing sample 
preparation time, use of organic solvents and disposal cost. There are two types of extraction 
modes for SPME: direct immersion of fibre into liquid sample matrix, (DI-SPME) and head-
space (HS-SPME) extraction in which the liquid sample matrix is heated in a vial to 
volatilize the analytes and the fibre is placed just above the sample matrix. In a typical 
protocol, the two essential steps are extraction and desorption. Conditions such as pH, salt 
concentration, sample volume, sample agitation/stirring speed, extraction temperature and 
extraction time strongly affect the extraction efficiency and must be optimized. For 
desorption SPME offers various options, when coupled to GC thermal desorption within the 
GC injector is possible while in LC desorption is carried out by a suitable solvent. A great 
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advantage of SPME is that derivatization and extraction can be performed simultaneously on 
the fibre.  
Various commercially available fibre coatings are polydimethylsiloxane, polyacrylate, 
polydimethylsiloxane-divinylbenzene etc. which allow the extraction of analytes of different 
polarities. In addition selective microextraction coatings have been developed based on 
antibodies, aptamers [137], and molecularly-imprinted polymers (MIPs) [138]. The fibres 
are easy to reuse. SPME is widely used in forensic toxicology and most applications have 
been reviewed by Pragst [139]. 
Stir bar sorptive extraction (SBSE) is a development of SPME and instead of fibre, the 
extraction phase is coated onto magnetic stir bars. The stir bar is added to the sample and the 
solution is stirred, analytes will partition between the sample matrix and the extraction 
phase; the extraction of an analyte from the aqueous phase into the extraction medium is 
controlled by its partitioning coefficient between the sorbent phase and the aqueous phase. In 
SBSE the volume of polymer coated onto the bar is 50-250 times larger than in SPME [140] 
and so SBSE afford greater recoveries. Similar to SPME, SBSE can be used by direct 
immersion (DI) and head-space (HS). The main drawback of this technique is the duration of 
extraction, typically 20-150 min which limits its application in routine analysis. In illicit 
drug testing SBSE has been applied only in a few studies, for example for the extraction of 
amphetamines and ketamine from urine [141]. 
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Analysis in biological fluids  
 
µ-SPE for determination of illicit drugs in plasma, 
urine and oral fluids - 
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EXPERIMENTAL 
1. Chemicals and Reagents 
Amphetamine (AMP), methamphetamine (MAMP), MDA, MDEA, MDMA, cocaine 
(COC), benzoylecgonine (BZE), mescaline (MES), ketamine (K), phencyclidine (PCP), 
psilocybin (PSY) and internal standards (ISs) methamphetamine- d5, MDMA-d5, 
benzoylecgonine-d3 and phencyclidine-d5 were purchased from S.A.L.A.R.S. S.p.A. 
(Como, Italy). The purity of the reference compounds was ≥99%. All standards were 
provided at a concentration of 1 mg mL
-1
. Acetonitrile and methanol were of RS-Plus grade. 
Ultrapure water was produced by a Milli-Q Plus apparatus from Millipore (Bedford, MA, 
USA). All solvents were obtained from Sigma-Aldrich (Milwaukee, WI, USA).  
Individual stock solutions were prepared in methanol at 0.1 mg mL
-1 
(1 μg mL-1 for the ISs); 
working standard mixtures of the analytes were prepared by appropriate dilution of the 
standards in methanol at concentration of 10 μg mL-1 in methanol and stored at -20 °C.  
For the extraction procedure the following devices were used: ultrasonic bath Starsonic 18 
from Liarre (Bologna, Italy) and micro-centrifuge D3024 from Scilogex (Berlin, CT, USA). 
 
2. Sample Preparation 
μ-SPE extraction was performed using OMIX C18 tips from Varian (Palo Alto, CA, USA). 
The functionalized fibre was initially conditioned by flushing twice an ultrapure 
water/acetonitrile solution (1:1, v:v) and three times an ultrapure water/methanol solution 
(9:1, v:v) using an automatic propipette from Phenomenex (Bologna, Italy). 
Urine samples were diluted with ultrapure water (1:1, v:v), while plasma and OF were 
processed without prior manipulation. 180 μL of sample (plasma, OF or diluted urine) were 
then mixed with 20 μL of methanol containing ISs at a concentration of 1 µg mL-1. 
The mixed solutions were sonicated for 6 min at room temperature and centrifuged at 10,000 
x g for 5 min to remove the precipitated proteins. 100 μL of supernatant were then collected 
and passed through the tip by five load/release cycles of the pipette. After a washing step 
with 100 μL of ultrapure water, analytes elution was achieved using 100 μL methanol 
containing 10 mM formic acid. Four µL of the eluate was directly injected in the LC–
MS/MS system. 
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3. LC–MS/MS analysis 
The HPLC equipment consisted of a Series 200 Micro-LC Pump and a Series 200 
autosampler from Perkin Elmer (Norwalk, CT, USA). An API 2000 from PE-Sciex 
(Toronto, ON, Canada) equipped with a TurboIon-Spray source was used.  
The 11 analytes selected for the multi-class method were separated using a reverse phase C18 
Kinetex column from Phenomenex packed with core-shell particles (2.6 μm, 2.1 x 150 mm). 
A Phenomenex security GuardUltra Cartridge (packed with C18 particles) was also used to 
protect the column from damaging contaminants and microparticulate. The mobile phases 
were methanol:acetonitrile (1:1, v:v) (phase A) and 5 mM formic acid in water (phase B); 
the flow rate was 0.2 mL min
-1
 entirely transferred into the mass spectrometer source. The 
analyte separation was performed using a gradient elution according to the following steps: 
increase of the phase A from 0 to 25% in 0.5 min then to 45%, in 7 min and to 100% in 
another 3 min; afterwards the system is switched back to the initial conditions in 5 min. The 
complete separation of all substances occurred in 12 min. A timed switched valve (a 10 
routes Valco valve connected to the instrument) drived the effluent to the source only from 
minute 5.0 to 12.5 and then from 16.0 to 18.5. All the analytes were detected in positive 
ionization (PI) with a capillary voltage of 5,000 V, nebulizer gas (air) at 65 psi, turbo gas 
(nitrogen) at 35 psi and 400 °C; focusing potentials and entrance potential were set at 400 V 
and 10 V, respectively.  
Two multi-reaction monitoring (MRM) transitions were selected for each analyte. All source 
and instrument parameters for the monitored analytes were tuned by injecting each single 
standard solution at a concentration of 100 ng µL
-1
 at 10 μL min-1 by a syringe pump; all the 
source parameters have been checked (and revised as necessary) in flow injection analysis 
with the optimized chromatographic conditions.  
Peak areas for selected ions were determined using PE-Sciex package Multiview 1.5 and 
quantitation was performed by the IS method. The selected transitions, together with the 
main HPLC–MS/MS parameters, are reported in Table I.1. 
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Analyte 
Rt 
(min) 
Q1 
(amu) 
DP 
(V) 
Q3 
(amu) 
CE 
(V) 
CXP 
(V) 
Amphetamine 5.5 136.1 15 
91.2 28 4 
119.1 33 3 
Benzoylecgonine 8.2 290.1 50 
168.1 30 5 
105.0 44 6 
Cocaine 9.6 304.1 23 
182.3 29 3 
82.0 49 2 
Ketamine 8.0 238.1 21 
125.3 42 8 
179.3 26 7 
MDA 6.5 180.2 13 
163.3 16 5 
105.1 33 5 
MDEA 7.6 208.1 21 
163.2 20 5 
105.1 37 7 
MDMA 6.9 194.2 20 
163.2 20 5 
105.1 37 5 
Mescaline 6.6 212.0 19 
195.2 29 5 
180.2 10 4 
Methamphetamine 6.1 150.0 22 
91.1 31 3 
119.1 16 2 
Phencyclidine 10.7 244.2 10 
159.3 21 8 
91.2 58 10 
Psilocybin 5.4 285.0 138 
58.2 45 6 
225.2 20 5 
BZE-d3 8.2 293.1 50 171.1 30 5 
MDMA-d5 6.9 199.2 20 165.2 20 5 
MAMP-d5 6.1 155.2 22 121.3 16 2 
PCP-d5 10.7 249.2 10 164.2 21 8 
     Table I.1. HPLC–MS/MS conditions for selected analytes and ISs  
4. Validation 
Methods were fully validated according to SOFT-AAFS guidelines [3] and Peters et al. 
[142]. For this purpose the following parameters were evaluated: limits of detection (LODs) 
and limits of quantitation (LOQs), linearity, precision, accuracy, recovery, stability, matrix 
effect, specificity and carryover. Calibration standards were prepared in 10 mM formic acid 
in methanol, while quality control (QC) samples, used for validation experiments were 
prepared in authentic matrix. 
4.1 Linearity, selectivity and carryover 
Calibration standards were prepared at six concentration levels in three replicates each one. 
Linearity was checked from LOQ to 100 ng mL
-1
 in plasma, LOQ to 200 ng mL
-1
 in OF and 
LOQ to 1000 ng mL
-1
 in urine.  
Analyte responses were normalized to internal standards and quantified from calibration 
standards by linear least-squares regression.  
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Two product ions were selected for each compound, one for quantitation and one for 
qualitative analyte confirmation. For identification quantitative to qualitative ion ratios were 
required to be within 20% of those in QC samples. The presence of any matrix interferences 
at the retention time of the selected analytes was observed by analysing ten blank samples of 
urine, plasma and OF. 
Carryover phenomena has been verified by injecting the calibrators, spaced with injections 
of pure methanol, at increasing and decreasing concentration in triplicate. 
 
4.2 LODs and LOQs 
LODs represent the smallest concentration of a drug needed to give a peak height three 
times the noise level of the background signal from a blank sample. According to 
SOFT/AAFS guidelines [5], LODs were derived experimentally  on the analyte MRM 
transition with lowest S/N analyzing blank OF samples and blank samples spiked with 
decreasing amount of standard solution at the appropriate concentration; LOQs were 
determined similarly as the smallest concentration of a drug needed to give a peak height ten 
times the noise level of the background signal from a blank sample. In addition quantifier to 
qualifier ratios within ±20% of mean QC and both accuracy and precision within ±20% were 
required at LOQ level. 
 
4.3 Accuracy and Precision 
Accuracy and precision were determined at three concentration levels:  
 20, 50 and100 ng mL-1 in plasma and OF. 
  ½ cut-off, cut off, and 1.5 cut off values in urine  
Precision was expressed as the relative standard deviation RSD (%); intra-day precision 
(repeatability) was calculated for each analyte, from the areas of six independent samples 
spiked before extraction, for each concentration level; inter-day precision (reproducibility) 
was obtained from the areas of 18 spiked samples analyzed over six days (six independent 
samples per day). Accuracy was estimated from six samples spiked before extraction step; 
the concentration relative to the mean peak area (Cc), was calculated by the calibration 
curve equation and was compared with the theoretical concentration (Ct). Accordingly A% 
= Cc/Ct × 100. 
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4.4 Recovery and matrix effect 
Recovery (R%) was calculated at three concentration levels (see above § 4.3.). 
Six QC samples for each concentration were spiked with the appropriate amount of standard 
stock solution and processed, while an equal number of samples were processed as blanks 
and spiked with the same amount of standard stock solutions after the clean-up step. 
Recovery values were obtained by comparing, for each analyte, the mean peak area of 
samples spiked before the extraction (A) with the mean peak area obtained when the 
analytes were spiked after the extraction procedure (B). Accordingly, R(%) = A/B × 100. 
The interference of the matrix on the S/N ratio of each analyte was calculated comparing the 
slopes of two calibration curves, one obtained in solvent and the other prepared in a pool 
constituted by 20 independent matrices. Furthermore 6 independent blank samples were 
spiked at a concentration corresponding to three times the LOQ for each analyte, to assess 
the variability of the matrix effect. 
 
4.5 Stability 
Stability tests were run on processed QC samples fortified with the analytes and standard 
solutions in methanol both for short term and long term stability (two months). In addition 
real samples spiked with the analytes and kept at -20°C were analyzed over several days for 
the full term of 2 months.  
To assess short term stability processed samples and standard solutions were kept at -20°C 
and three different concentration levels were analyzed at t = 0, 1,7, 14 days. For long-term 
stability, processed samples were analyzed over several days (t = 0, 30, 60) for the full term 
of 2 months. The influence of three freezing/thawing cycles was also evaluated. Responses 
were compared to the t = 0 samples amount. 
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RESULTS AND DISCUSSION 
In this part, a miniaturized SPE techniques, namely µ-SPE, has been tested for the extraction 
of drugs belonging to different classes from urine, plasma and OF. The method, initially 
developed for OF drugs determination, was later extended and harmonized by including the 
two conventional matrices. 
Different procedures based on liquid chromatography–mass spectrometry (LC–MS) and LC–
MS/MS for determination of drugs in OF: an exhaustive review of whole analytical 
procedures necessary for the determination of drugs of abuse (sampling, pre-treatment, 
analysis conﬁrmation) has been reported by Samyn [143]. Recent studies on OF have 
demonstrated the usefulness of LC–MS for the determination of illicit drugs[144] and for the 
identiﬁcation and quantitation of amphetamines, cocaine, opiates, and phencyclidine in oral 
ﬂuid by LC–MS/MS [145]. Ultraperformance LC–MS/MS assay for 29 illicit drugs and 
medications and simultaneous screening and quantiﬁcation in OF has been also reported 
[146, 147]. LC–MS methods, however, present problems related to matrix effects in terms of 
endogenous compounds such as salts, proteins or metabolites [83, 148, 149]. Thus, because 
of the high viscosity of OF due to the presence of mucine, a clean-up step is necessary prior 
to analysis [150] Some authors have also described a direct injection in OF and blood [151]. 
Many LC–MS methods for the determination of drugs of abuse in plasma have been 
published, for example, for the determination of cocaine and its metabolites [152, 153], 
amphetamines and designer drugs [154]; only few methods for the simultaneous 
determination of amphetamine, BZE and cocaine in plasma have been reported [96, 151, 
155]. Sample pre-treatment consisted rarely in a simple protein precipitation (PPT); usually a 
SPE step was used in addition. Several methods for the simultaneous determination of 
amphetamine, designer drugs, cocaine and metabolites based on LC–MS/MS in urine have 
been published [60, 156], but not including hallucinogens; a direct injection (after ten-fold 
dilution of matrix) LC–MS/MS method for the identification and quantification of 
amphetamine, methamphetamine, MDA and MDMA in urine drug testing has been 
developed by Andersonn et al. [157] and a work describing a procedure by SPE followed by 
UPLC–MS/MS has been also reported [158]. 
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1. LC–MS/MS conditions 
To improve selectivity and sensitivity of both methods, Kinetex chromatographic columns, 
with Core–ShellTM  technology with an average diameter of particles 2.6 microns, were used.  
The use of columns with superficially porous packing materials is a relatively recent trend in 
chromatographic separation. These columns allow greater separation efficiency and speed of 
analysis by reducing the diffusion of the analytes. With reference to the Van-Deemter 
equation, their use dramatically improves chromatographic efficiency by the combination of 
a lower axial diffusion (due to the solid core of the particle) and a lower eddy dispersion 
term (due to narrow particle size distribution). The advantage of using columns with 
superficially porous packing materials is their greater efficiency in high speed analysis 
without the generation of high back-pressures, which is typical in UPLC and requires for 
special LC equipment. 
In the multi analyte method here developed, the main problem in the chromatographic set-up 
was the separation of the amphetamine type molecules that exhibited the same ion 
fragments. We selected a column of 15 cm which gave a better resolution, compared to an 
identical column of 10 cm. In addition to obtain an increased resolution the influence of a 
certain amount of acetonitrile in the organic phase, consisting solely of methanol, has been 
tested. These tests, carried out at different percentage, resulted in an increase in selectivity 
using 10% acetonitrile, no further improvement for higher amounts was achieved. The 
stability of the LC method was evaluated by calculating the retention time variations. The 
RSD, calculated from retention times obtained over 30 injections, proved to be less than 
2.0% for all compounds. The performances of core shell columns were evaluated comparing 
a Gemini C18 column, previously used in our laboratory, with a Kinetex. It was verified that 
the latter column allowed to reach detection limits substantially lower (about three fold) for 
the considered analytes in biological samples. In Fig. I.1. the extracted ion currents for the 
selected analytes, obtained from the analysis of a fortified blank sample are reported. 
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Figure I.1. Extracted ion currents of the selected MRM transitions (only quantifier) obtained 
from the analysis of a plasma sample spiked with the analytes. 
 
2. Clean-up optimization 
This procedure has been applied on plasma, OF and urine samples. Compared to classic SPE 
this technique allows the sample pretreatment in a shorter time and it allows to use only 100 
µL of sample; this is particularly useful when dealing with plasma samples. 
The procedure was optimized similarly to a traditional SPE. The maximum allowed 
concentration of organic solvent for sample pre-treatment (partial protein precipitation) was 
initially studied: a sensitive decrease in the analyte retention was observed using methanol 
concentrations higher than 10%, particularly for polar molecules such as amphetamine or 
mescaline and for this reason 10% was finally selected. The optimal number of 
aspirate/dispense cycles was also evaluated, testing 1 to 10 cycles and it was found that no 
further increases were obtained with more than 5 cycles.  
The extraction performances were evaluated by measuring the analyte content in five 
fractions: the first was the analyte loading solution, ultrapure water:methanol solution (9:1, 
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v:v), and represented the percentage of the analyte unretained by the tip; the second was the 
analytes lost during the washing step with water; while the third, fourth and fifth fractions 
were the amount of analyte recovered after three subsequent acidified methanolic fraction 
elutions (100 µL containing 10 mM formic acid). The absolute recoveries are lower for more 
polar substances such as amphetamine and psilocybin (55–60%), while they can be 
considered almost quantitative for cocaine and phencyclidine. Capacity of the tips for the 
specific analyte was checked along the concentration range of analysis, especially for urine 
in which the range of concentrations investigated is wider. The analytical results have shown 
that there are no saturation phenomena in the tested range of concentration . 
The present procedure has been attempted also for other classical drugs of abuse. However, 
retention of opiates was not satisfactory in the optimized conditions (lower than 50%), while 
detection of cannabinoids was achieved below the suggested cut-off levels. For these 
reasons both types of drugs were not included in the validation study. 
 
3. Validation 
3.1 Linearity, LODs and LOQs 
Methamphetamine-d5, MDMA-d5, BZE-d3 and phencyclidine-d5 were used as ISs for their 
analogues and also for the other compounds with a similar chromatographic behavior or 
structure affinity. The linearity was satisfactorily described by un-weighted least-squares 
linear regression; as reported in Table I.2, the average determination coefficients (r
2
) are 
above 0.99 as required by the SOFT/AAFS guidelines [5].  
Linear range has been selected in order to include the concentrations normally found in real 
samples; concentrations up to 1000 ng mL
-1
 are tested only for urine, where high 
concentrations of drugs are normally found. 
The blank samples injected between calibrators always exhibited no carryover phenomena; 
QCs were always within the limits of precision of the method. LODs were derived 
experimentally as suggested by the SOFT/AAFS guidelines to better determine the true 
LOD in chromatographic assays [5] and are reported in Table I.2. To ensure identification of 
the analytes even at the level of LODs, the latter were calculated for each analyte on the 
MRM transition having the lowest S/N. LOQs were calculated in a similar way: an 
acceptable relative standard deviation (±20%) can be routinely achieved at the lowest 
concentration of calibrator. 
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Analyte Internal std Equation r
2 
LOD  
(ng mL
-1
) 
LOQ  
(ng mL
-1
) 
 
Plasma (range= LOQ-100 ng mL
-1
) 
Amphetamine Methamphetamine-d5 y=0.0319x-0.0054 0.9990 0.6 1.9 
Benzoylecgonine Benzoylecgonine-d3 y=0.0476x-0.0309 0.9988 0.5 1.6 
Cocaine Benzoylecgonine-d3 y=0.0306x-0.0309 0.9995 0.05 0.2 
Ketamine Methamphetamine-d5 y=0.0353x+0.0157 0.9994 0.2 0.7 
MDA MDMA-d5 y=0.0148x+0.0074 0.9996 1.8 5.9 
MDEA MDMA-d5 y=0.0219x+0.0205 0.9995 1.0 3.3 
MDMA MDMA-d5 y=0.0198x-0.0053 0.9992 0.9 2.7 
Mescaline Methamphetamine-d5 y=0.0357x+0.0372 0.9993 0.5 1.7 
Methamphetamine Methamphetamine-d5 y=0.0897x-0.0712 0.9994 0.8 2.4 
Phencyclidine Phencyclidine-d5 y=0.0309x-0.0368 0.9990 0.3 1.0 
Psilocybin Methamphetamine-d5 y=0.0210x-0.0046 0.9996 1.2 3.9 
 
OF (range=LOQ-200 ng mL)
-
 
Amphetamine Methamphetamine-d5 y=0.0289x+0.0140 0.9980 0.3 1.5 
Benzoylecgonine Benzoylecgonine-d3 y=0.0420x+0.0052 0.9999 0.2 0.8 
Cocaine Benzoylecgonine-d3 y=0.0320x+0.0039 0.9956 0.05 0.2 
Ketamine Methamphetamine-d5 y=0.0321x+0.1101 0.9980 0.3 1.0 
MDA MDMA-d5 y=0.0261x+0.0038 0.9985 1.2 2.9 
MDEA MDMA-d5 y=0.0471x+0.0210 0.9982 0.4 2.3 
MDMA MDMA-d5 y=0.0170x+0.0011 0.9970 0.3 1.9 
Mescaline Methamphetamine-d5 y=0.0182+0.0157 0.9943 0.1 1.0 
Methamphetamine Methamphetamine-d5 y=0.0101+0.0098 0.9978 0.2 0.6 
Phencyclidine Phencyclidine-d5 y=0.0268+0.01253 0.9986 0.1 0.4 
Psilocybin Methamphetamine-d5 y=0.0184+0.00521 0.9954 1.0 3.0 
 
Urine (range=LOQ-1000 ng mL
-1
) 
Amphetamine Methamphetamine-d5 y=0.0248x+0.0340 0.9986 0.7 2.3 
Benzoylecgonine Benzoylecgonine-d3 y=0.0863x+0.0359 0.9979 0.4 1.3 
Cocaine Benzoylecgonine-d3 y=0.0392x+0.0359 0.9994 0.02 0.06 
Ketamine Methamphetamine-d5 y=0.0209x+0.0271 0.9997 0.3 1.0 
MDA MDMA-d5 y=0.0992x+0.0541 0.9992 2.0 6.6 
MDEA MDMA-d5 y=0.0161x+0.0028 0.9980 0.5 1.7 
MDMA MDMA-d5 y=0.0132x-0.0675 0.9993 1.0 3.3 
Mescaline Methamphetamine-d5 y=0.0220x+0.0015 0.9995 0.3 1.0 
Methamphetamine Methamphetamine-d5 y=0.0371x-0.0376 0.9993 1.0 3.3 
Phencyclidine Phencyclidine-d5 y=0.0585x-0.0012 0.9995 0.1 0.3 
Psilocybin Methamphetamine-d5 y=0.2212x-0.0015 0.9992 142 5.6 
Table I.2. Regression data, LODs and LLOQs for selected analytes in plasma, OF  and urine 
 
These low detection limits have been achieved using the best conditions for the detection 
together with the clean-up strategy that allows the enrichment of the analytes maintaining a 
low matrix effect. The LOQs obtained for all the analytes in urine are lower than the cut-off 
values reported by SAMSHA [2]. 
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3.2 Accuracy and precision 
Accuracy and precision were assessed using fortified drug-free matrix. Accuracy is very 
close to 100% for most analytes and always within ± 15% . Intraday and intermediate 
reproducibility, in term of RSD, were constantly < 15%.  
In urine precision, accuracy and recovery have been calculated at three concentration values, 
corresponding to ½ cut off, cut off and 1,5 cut off for each analyte. For some analytes cut-
off values were not available and the three concentrations were chosen over the entire range. 
The experiments showed that the analytical performances of the method were independent 
of concentration. All precision and accuracy data are reported in Table I.3 
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Analyte Plasma 
Nominal Conc  
(ng mL-1) 
Intra-day  
(n=6) 
Inter-day 
(n=18) 
Recovery 
(%) 
ME 
  RSD% A% RSD%   RSD% 
Amphetamine 20 4 98 7 55 1.09 6 
50 6 98 6 56 
100 9 100 5 56 
Benzoylecgonine 20 5 100 7 73 1.08 6 
50 7 101 7 79 
100 3 101 4 75 
Cocaine 20 2 101 3 82 1.06 5 
50 3 102 3 85 
100 1 101 2 79 
Ketamine 20 6 102 6 80 1.06 5 
50 5 103 6 84 
100 4 102 4 82 
MDA 20 7 98 12 63 1.09 4 
50 7 97 7 65 
100 7 99 9 66 
MDEA 20 2 105 6 78 1.08 7 
50 2 102 3 79 
100 2 103 4 80 
MDMA 20 7 100 8 70 1.06 7 
50 5 101 7 68 
100 5 100 6 72 
Mescaline 20 4 103 5 62 1.07 6 
50 7 100 5 63 
100 5 99 4 63 
Methamphetamine 20 3 99 4 67 1.06 9 
50 3 101 4 69 
100 5 101 6 71 
Phencyclidine 20 2 99 3 85 1.07 8 
50 2 100 4 87 
100 2 100 3 86 
Psilocybin 20 7 97 7 61 1.07 9 
50 5 98 5 60 
100 3 97 4 63 
Table I.3. Intra and inter day precision (expressed as RSD%), accuracy (A%), recovery and 
matrix effect (ME) data for selected analytes in plasma, OF and  urine (see next pages) 
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Analyte OF       
Nominal Conc  
(ng mL-1) 
Intra-day  
(n=6) 
Inter-day 
(n=18) 
Recovery 
(%) 
ME 
Amphetamine 20 6 95 7 64 1.06 6 
50 6 97 5 65 
100 4 97 6 64 
Benzoylecgonine 20 7 101 6 82 1.05 6 
50 6 99 7 79 
100 5 100 7 80 
Cocaine 20 6 103 8 84 1.06 5 
50 4 101 5 87 
100 5 98 5 81 
Ketamine 20 6 102 8 85 1.03 9 
50 4 100 5 80 
100 4 105 7 83 
MDA 20 3 97 5 70 1.05 6 
50 5 97 4 68 
100 4 99 4 70 
MDEA 20 6 96 8 79 1.08 5 
50 5 100 7 80 
100 6 97 5 76 
MDMA 20 4 99 7 74 1.03 9 
50 5 98 6 72 
100 3 100 6 75 
Mescaline 20 7 100 8 64 1.06 7 
50 7 98 7 63 
100 6 102 8 63 
Methamphetamine 20 5 100 6 75 1.04 7 
50 3 99 4 73 
100 2 102 4 70 
Phencyclidine 20 7 103 8 87 1.03 4 
50 5 101 6 81 
100 4 98 5 83 
Psilocybin 20 6 95 6 63 1.07 6 
50 4 97 4 60 
100 3 95 5 61 
Table I.3. Intra and inter day precision (expressed as RSD%), accuracy (A%), recovery and 
matrix effect (ME) data for selected analytes in plasma, OF and  urine (see previous and next 
page) 
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Analyte Urine    
Nominal Conc  
(ng mL-1) 
Intra-day  
(n=6) 
Inter-day 
(n=18) 
Recovery 
(%) 
ME 
Amphetamine 250 7 98 8 58 1.08 5 
500 8 97 9 61 
750 6 96 7 59 
Benzoylecgonine 75 8 103 7 83 1.06 4 
150 3 101 4 88 
225 7 99 7 80 
Cocaine 0.1 3 100 4 85 1.08 7 
5 1 101 2 85 
100 2 102 3 86 
Ketamine 250 5 102 5 84 1.07 5 
500 10 104 3 86 
750 3 103 3 88 
MDA 250 7 97 10 70 1.09 5 
500 3 98 8 72 
750 7 96 7 76 
MDEA 250 5 101 6 78 1.08 9 
500 6 100 7 81 
750 5 102 5 83 
MDMA 250 7 100 7 76 1.01 2 
500 3 99 3 79 
750 3 100 4 81 
Mescaline 250 4 97 4 66 1.08 5 
500 5 96 7 65 
750 2 96 2 66 
Methamphetamine 250 6 100 7 74 1.07 6 
500 4 99 4 73 
750 3 101 4 79 
Phencyclidine 12.5 3 99 4 89 1.02 6 
25 1 100 2 88 
37.5 1 102 2 90 
Psilocybin 12.5 7 96 7 57 1.06 8 
25 5 97 5 63 
37.5 5 95 6 65 
Table I.3. Intra and inter day precision (expressed as RSD%), accuracy (A%), recovery and 
matrix effect (ME) data for selected analytes in plasma, OF and  urine (see prevous pages) 
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3.3 Matrix effect and selectivity 
During the optimization of the multi-class method, dilution of matrix with ultrapure water 
was tested to reduce ion suppression (1:1, 1:2, 1:5 and 1:10 dilution). Dilution 1:1 v:v, for 
urine was a good compromise to reduce matrix effects with acceptable loss of sensitivity, 
taking into account that the SAMHSA cut-off values are relatively high. Plasma dilutions 
caused considerable decrease of sensitivity without gain in terms of matrix effect. The 
variability of the matrix composition has proved to be a critical point in OF: this 
phenomenon was not evident analyzing pools of saliva, but it was observed on samples from 
individuals, among which there were also possibly positive cases. This was one of the major 
issues to address in the development of the µSPE procedure. To assess the variability of the 
matrix effect between samples, which can be considered as important as ME value [89], six 
different blank matrix sources were spiked with the analytes after the extraction step and 
were analyzed. The RSD% is shown in table I.3 together with the ME obtained by the ratio 
between the slopes of the calibration curves in solvent and in matrix. The proposed 
analytical procedures have demonstrated to strongly reduce matrix effect: signal ion 
suppression affected the sensitivity always less than 15%. These analytical results indicated 
that it is possible to use a calibration curve in solvent, as previously described, for the 
quantitation of the selected analytes in the three matices. 
Only a small number of interfering signals, at different retention times, were recorded from 
the analyses of drug-free samples, demonstrating that the developed methods provided good 
selectivity for all the considered analytes. 
 
3.4 Stability 
Stability tests were run for working standard solutions and processed samples. Keeping 
solutions at −20◦C during the inter-day assays, both for long term and short term stability 
experiments, the intensity of signal of the MRM transitions were no significantly different 
for all the analytes. The analytes were not affected even by repeated freezing-thawing 
cycles: the calculated concentration of storage and freshly prepared samples were within 
intermediate reproducibility values of the methods.  
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Part II 
Hair 
Analysis in unconventional biological sample 
 
Pressurized liquid extraction for the extraction of 
illicit drugs from hair 
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EXPERIMENTAL 
1. Chemicals 
 
Standards of AM, MA, MDA, MDEA, MDMA, COC, BZE, MES, codeine (COD), 
morphine (MOR), 6-acetylmorphine (6-MAM), K, PCP MOR-d3, MA-d9, MDMA-d5, CO-
d3, BE-d3, and PCP-d5were purchased from S.A.L.A.R.S. S.p.A. Norcocaine (NCOC) was 
obtained from Cerilliant Corporation (Round Rock, TX, USA). THC, THC-COOH, CBD, 
CBN, OH-THC, THC-d3, THC-COOH-d3 and cocaine-d3 (COC-d3) were purchased from 
LGC Standards (Wesel, Germany). The purity of the reference compounds was ≥99 %. All 
standards were provided at a concentration of 1 mg mL
-1
 with the exception of ISs that were 
at a concentration of 0.1 mg mL
−1
.  
Individual stock solutions were prepared in methanol at 0.1 mg mL
-1
, except for the ISs 
which were prepared at 1 μg mL-1. Working standard mixtures were prepared by appropriate 
dilution of the standards in methanol. All solutions were stored at -20°C in the dark. 
Acetonitrile and methanol were of RS-Plus grade. Ultrapure water for LC was produced by a 
Milli-Q Plus apparatus from Millipore. All solvents, hydrochloric acid, and potassium 
dihydrogen phosphate, used for preparation of aqueous buffer, were purchased from Carlo 
Erba. Formic acid, sodium hydroxide and sodium dodecylsulphate (SDS) were from Sigma–
Aldrich  
 
 
2. External decontamination 
Crudely cut hair (~1 cm) was placed in a 50 mL Falcon cone tube and 5 mL phosphate 
buffer (0.1 mol L
-1
, pH 6) was added. The mixture was vortex mixed for 1 min and, after 
removal of the aqueous buffer, the hair was washed sequentially with 5 mL of isopropanol 
and 5 mL of dichloromethane. 
The last wash was collected in a vial and evaporated under a gentle stream of N2; the residue 
was reconstituted with 1 mL of 10 mmol L
-1
 formic acid in methanol and was checked for 
external contamination. 
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3. Pressurised liquid extraction 
Extraction of target analytes from hair was performed by pressurised liquid extraction (PLE) 
using a Dionex ASE 200 (Sunnyvale, CA, USA) accelerated-solvent-extraction system. Two 
different extraction methods were developed: a multiclass method including 14 analytes and 
a specific one for cannabinoids. A sample of hair (50 mg) cut into 1–2 mm segments was 
homogenized with Varian Hydromatrix bulk sorbent (Palo Alto, CA, USA) by means of a 
mortar. The mixture was then placed in a 1 mL pressure resistant stainless steel cell, which 
was sealed at both ends with glass fibre filters. Void volumes in the cell were filled with 
Hydromatrix bulk sorbent, and 25 μL of methanol containing the ISs were added. PLE was 
performed with a single extraction cycle, using as extraction solvent SDS 25 mM in 
water:methanol (90:10, v/v) for cannabinoids extraction and water:methanol (80:20, v/v) for 
the other analytes. The extraction conditions were: pressure, 100 bar; temperature, 150 °C; 
preheat time, 1 min; heat time, 7 min; static time, 5 min; flush volume, 0 %; purge time, 60 
s. The PLE extract (6–8 mL) was automatically collected in glass vial with cap and solvent-
resistant PTFE septa. 
 
4. Clean-up of extracts 
1.1 Multi-class method 
The PLE extract was collected in a graduated tube and 4 mL were cleaned by SPE on a 
polymeric reversed-phase cartridge (Strata X 30 mg/1 mL from Phenomenex, Torrance, CA, 
USA). The cartridge, installed on the Visiprep vacuum system, had previously been 
conditioned with 1 mL methanol and 1 mL of water:methanol (80:20, v/v) After the loading 
phase, the cartridge was washed with 1 mL of ultrapure water and the analytes were eluted 
with 0.5 mL of 10 mmol L
-1
 formic acid in methanol, collected in a vial for analysis; two µL 
were injected, 
1.2 Cannabinoids 
PLE extract was collected into a graduated tube and centrifuged at 6000 g for 5 min at 25°C 
(ALC PK 121R, Thermo Scientific Inc., Bremen, Germany). Five mL were then cleaned up 
by SPE using polymeric reversed phase cartridges Strata X 30 mg/1 mL from Phenomenex 
(Torrance, CA, U.S.A.). The cartridge, installed on vacuum system Visiprep, was previously 
conditioned with 1 mL of methanol and 1 mL of water-methanol (90:10 v/v). Following the 
loading phase, cartridge was washed with 3 mL of water-methanol (50:50 v/v) and after 
drying under vacuum the analytes were eluted with 1 mL of ammonium hydroxide 50 mM 
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in methanol. The eluate was collected into a glass tube, evaporated to dryness under gentle 
nitrogen flow and the residues were finally reconstituted in 200 μL of methanol for injection 
in the LC-MS/MS system (10 μL). 
 
5. Preparation of a fortified matrix by soaking 
Positive hair was prepared in our laboratory following an existing procedure with slight 
modifications. Briefly, different types of hair (smooth, curly, coloured, treated, grey, etc.) 
were roughly cut and mixed. This mixture (8 g) was immersed in a mixture of 60 mL 
distilled water containing the substances of interest, and 60 mL 0.02 mol L
-1
 HCl in dimethyl 
sulfoxide. The hair, totally immersed and periodically mixed, was soaked in this solution for 
three weeks. 
It was then vacuum filtered on a Buckner funnel and let to dry. Dried hair was washed to 
remove traces of the analytes on its surface and then underwent the external decontamination 
procedure. 
 
6. LC–MS/MS analysis 
A PerkinElmer (Norwalk, CT, USA) series 200 micro-LC pump with autosampler (equipped 
with a 5 μL loop) and vacuum degasser system was used for chromatography. The LC 
system was coupled to a PerkinElmer Sciex API 2000 triple quadrupole mass spectrometer 
equipped with a TurboIonSpray source for the multi-class drugs analysis while an API 4000 
Qtrap® was used for the detection of cannabinoids. 
For both methods the analytes were separated on a reversed phase C18 Kinetex XB column 
(10 cm x 2.1 mm ID) from Phenomenex, packed with 2.6 μm average diameter particles; a 
KrudKatcher ultra HPLC in-Line filter 0.5 μm, also from Phenomenex, was used to protect 
the column.  
For the muli class-method the mobile phases were methanol:acetonitrile (90:10, v/v) (phase 
A) and 7 mmol L
-1
 formic acid in water (phase B); the flow rate was 0.4 mL min
-1
, entirely 
transferred into the mass spectrometer source. The gradient was: 0 % to 15 % A in 0.2 min, 
increased to 35 % A in 3.2 min, and then increased to 100% in 2.6 min. This was maintained 
for 2 min and then switched back to the initial 0 % in 2 min. Complete separation of all the 
substances was achieved in 6 min. A timed switch valve (a 10-port Valco valve connected to 
the instrument) was used to drive the effluent to the source from 1.5 to 6 min and then from 
8 to 10 min only. All the analytes were detected in positive-ionization mode with a capillary 
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potential of 5500 V, focusing potential of 400°C, nebulizer gas at 40 psi, turbo gas at 90 psi, 
and curtain gas at 30 psi; the source temperature was 400 °C. The MRM ion currents were 
acquired in two acquisition periods, to ensure maximum sensitivity of MS analysis. In the 
first period (from 0 to 3.65 min) the analytes detected were MOR, COD, 6-MAM, MES, 
AM, MA, MDA, MDMA, and MDEA; in the second period (from 3.65 to 6min) KE, CO, 
NCO, BE, and PCP were detected. 
For cannabinoids analysis the mobile phases were: (A) methanol and (B) water both 
containing 1.25 mM ammonium acetate. The flow rate was 0.35 mL min
-1
 entirely driven 
into the ion source. The following gradient elution scheme was used: phase A was increased 
from the initial 60% to 75% in 3.4 min, then up to 90% in 1.7 min and in the following 0.6 
min brought to 100%. The latter was maintained for 2.7 min and then switched back to the 
initial 65% in 2.5 min. The complete separation of all substances occurred in 8 min. A timed 
switch valve (a 10-PORT Valco valve connected to the instrument) drives the effluent to the 
source only from minute 4.5 to 8 and then from 10 to 12. All the analytes were detected in 
positive ionization, except THC-COOH that was analyzed in negative ionization, with a 
capillary voltage of 5500 V (-4500 V for THC-COOH), nebulizer gas at 60 psi, turbo gas 
(nitrogen) at 40 psi and curtain gas at 30 psi; the source temperature was 475°C. 
In both methods for each analyte two multiple reaction monitoring (MRM) transitions 
were selected. All source and instrument conditions for the monitored analytes were tuned 
by injecting each single standard solution at a concentration of 0.1 ng μL-1 at 10 μL min-1 
by use of a syringe pump. All the source conditions were checked (and revised as 
necessary) by flow-injection analysis with the same chromatographic conditions (flow 
and solvent composition).  
Peak areas for the selected ions were determined by use of the PE-Sciex package 
Multiview 1.5 and quantification was performed by the internal standard method. The 
selected transitions, with the main LC–MS/MS conditions, are reported in Table II.1. and 
II.2.  
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Period Analyte tR 
(min) 
Q1 
(amu) 
DP 
(V) 
EP 
(V) 
Q3 
(amu) 
CE 
(V) 
CXP 
(V) 
1 Morphine 1.72 286.0 42 11 201.2 35 8 
153.2 53 10 
Codeine 2.29 300.0 90 12 165.1 55 5 
215.1 33 4 
6-MAM 2.79 328.0 40 11 165.2 55 7 
211.1 37 5 
Mescaline 2.78 212.1 17 4 195.2 15 8 
165.2 32 6 
Amphetamine 2.44 136.1 14 8 91.1 25 11 
119.2 14 5 
Methamphetamine 2.61 150.0 18 9.2 91.1 26 10 
119.2 16 5 
MDA 2.74 180.1 18 8 163.1 15 7 
105.1 30 8 
MDMA 2.87 194.1 18 6 163.2 17 5 
105.2 35 7 
MDEA 3.36 208.0 18 6 163.2 17 6 
105.1 35 10 
 Morphine-d3 1.72 289.0 42 11 165.0 54 10 
MDMA-d5 2.87 199.1 18 6 165.1 17 2 
2 Ketamine 3.95 238.0 22 6 125.0 37 6 
207.1 17 6 
Benzoylecgonine 5.18 290.0 25 10 168.2 25 6 
105.2 40 12 
Cocaine 4.50 304.0 26 8 182.2 26 5 
82.2 45 9 
Norcocaine 4.90 290.0 20 9.2 168.2 21 5 
136.2 31 4 
Phencyclidine 5.37 244.1 11 8 86.1 18 11 
91.1 42 11 
BZE-d3 5.18 293.1 25 10 171.1 25 6 
COC-d3 4.50 307.0 26 8 184.9 26 5 
PCP-d3 5.37 249.0 11 8 91.0 18 11 
   Table II.1.HPLC–MS/MS parameters for the selected analytes (multi-class method) 
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Period Analyte 
tR 
(min) 
Q1 
(amu) 
DP 
(V) 
EP 
(V) 
Q3 
(amu) 
CE 
(eV) 
CXP 
(V) 
1 
THC-COOH 2.84 343.1 -95.1 -8 
299.5 -29.7 -12.3 
345.2 -38.2 -10 
THC-COOH-d3 2.84 346.1 -95.1 -8 302.5 -29.7 -12.3 
2 
THC 6.00 315.1 64.9 10.8 
193.1 30.1 11.5 
123.2 45.1 6.1 
CBN 5.59 311.1 86.7 11 
223.1 30.7 14.1 
293.3 24.1 13.3 
CBD 3.95 315.1 64.9 10.8 
193.1 30.1 11.5 
123.2 45.1 6.1 
OH-THC 3.71 331.1 69.9 10.9 
193.0 33 11.6 
201.2 33 12.6 
THC-d3 6.00 318.1 64.9 10.8 196.1 30.1 11.5 
Table II.2. HPLC–MS/MS parameters for the selected analytes (cannabinoids) 
 
7. Validation 
The method was validated according to SoHT guidelines [71] and Peters et al. [142] with a 
few modifications. Linearity, recovery, matrix effect, precision, accuracy, limits of detection 
(LODs) and limits of quantification (LOQs) were evaluated. 
Calibration standards were prepared in methanol. Quality control samples (QC) were 
prepared by spiking the standard solution on the hair in the ASE cell; in addition certified 
reference material (CRM), real positive hair samples and positive hair prepared in our 
laboratory by soaking, were used for accuracy, precision and recovery studies.  
The CRM was Medidrug DHF 1/08-A H-Plus, distributed by LGC Standards (Wesel, 
Germany). It is a powdered hair control, prepared from spiked hair samples of human origin. 
This material only contained some of the analytes of interest (MOR, 6-MAM, AMP, 
MAMP, MDA, MDMA, MDEA, CO, BZE, THC, CBN, CBD). 
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7.1 Quantification and identification 
Linearity was investigated using six calibration standards for each group in the following 
concentration ranges: 
 from LOQ to 10 pg mg-1 for THC-COOH and to 200 pg mg-1 for CBD, CBN, THC 
and OH-THC: 
 from LOQ to 12.5 ng mg-1 for COC, to 1.25 ng mg-1 for BZE and NCOC and to 5 ng 
mg
-1
.for the remaining analytes. 
Replicates (n=3) at each concentration level were analyzed during two days. The calibration 
curves were derived by plotting the peak area of analytes to ISs versus the hair concentration 
using a least squares regression model.  
Two product ions were selected for each analyte, one for quantitation and one for qualitative 
analyte confirmation. Quantitative to qualitative ion ratios were required to be within 20% of 
those in QC samples. 
 
7.2 Recovery  
The recoveries (RE) and extraction efficiencies were determined at two concentration levels: 
 0.2 and 10 pg mg-1 for THC-COOH, 2 and 200 pg mg-1 for THC, CBN, CBD and 
OH-THC 
 4 pg mg-1 and 12.5 ng mg-1 for COC; 7 pg mg-1 and 1.25 ng mg-1 for BZE; 30 pg mg-
1
 and 5 ng mg
-1 
for the other analytes. 
Five hair samples of different types (blond, black, straight and curled) were used. For each 
concentration and hair type, RE were obtained by comparing the absolute peak area for each 
analyte when spiked into hair before extraction (A) with the absolute peak area for each 
analyte of samples processed as hair blanks and spiked after the extraction (B). Accordingly, 
RE(%) = A/B*100. 
 
7.3 Matrix effect, selectivity and carry-over 
Interferences from endogenous hair components were evaluated by the analysis of 10 
different drug-free hair samples collected among workers in the laboratory. If analytes were 
not detected (<LOD), the method was considered selective. In addition two samples, just 
spiked with the internal standards, were analyzed to check for the absence of the respective 
analyte peaks. 
Carry-over effects were assessed by analyzing a blank hair sample after injection of the 
highest calibrator. 
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The interference of the matrix on the S/N ratio of each analyte was calculated comparing the 
slopes of two calibration curves, one obtained in solvent and the other prepared in a pool 
constituted by 20 independent matrices and processed by PLE. Furthermore 6 independent 
blank hair samples were spiked at a concentration corresponding to three times the LOQ for 
each analyte, to assess the variability of the matrix effect. 
 
7.4 LODs and LOQs 
The LOD was estimated on the basis of four repeated analyses of fortified hair samples at 
decreasing concentrations. The LOD was calculated as the concentration where the signal to 
noise ratio (S/N) of 3:1 for the lower MRM transition was given. 
The LOQ was defined as the lowest concentration of fortified hair samples with both 
precision and accuracy within 20% with fulfillment of the retention time and ion ratio 
tolerances. Furthermore, a S/N above 10 was required. 
 
7.5 Accuracy and precision 
The method precision and accuracy were determined at two concentration levels on fortified 
hair samples (see above § 7.1.2). 
Each sample was analyzed four times on three days. The concentrations of the analytes were 
calculated from the daily calibration curves. Accuracy was calculated for each analyte in 
terms of bias, as the percent deviation of the mean calculated concentration at each 
concentration level from the corresponding spiked concentration. Within-day precision 
(repeatability) and inter-day precision (intermediate precision) were calculated as relative 
standard deviation (RSD%).  
The RSD% and bias were generally accepted at maximum values of 15% or 20% near 
LLOQ. 
Precision was further evaluated by analyzing positive real hair samples and positive hair 
prepared by soaking with varying content of the analytes. The determination was based on 
two replicates analyzed over four days.  
Accuracy was further evaluated with CRM for the analytes that were included in the sample. 
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7.6 Stability 
Stability tests were performed on processed samples and standard solutions in methanol. 
Tests were performed on short term storage solutions and for processed samples stored at 
-20°C, by analysis of the solutions on different days; long term stability was checked for a 
total time of two months. 
The effect of freeze–thawing cycles was also evaluated, as suggested by Peters et al. [46]. 
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RESULTS AND DISCUSSION 
1. LC–MS/MS optimization 
GC–MS has been the method of choice for confirming the detection of illicit drugs in hair; 
however, GC–MS requires analyte derivatization and, in fact, only a few multiclass methods 
have been reported. LC–MS does not need a derivatization step and, thus, facilitates 
multiresidue and multiclass analysis. Recently, with the introduction of ultra-high 
performance liquid chromatography (UPLC), the simultaneous screening and quantification 
analysis of 96 common drugs of abuse has been reported [159]. 
As regards cannabinoids analysis, to date the only techniques able to reach the cut-off of 0.2 
pg mg
-1
 recommended by SoHT [71] for THC-COOH determination in hair are gas 
chromatography coupled with tandem mass spectrometry (GC–MS/MS) using electron 
impact (EI) ionization mode [160, 161] or negative ion chemical ionization (GC-NCI–
MS/MS) that allows a further increase of the sensitivity [30-32] and GC/GC–MS [162]. LC–
MS/MS has been used in cannabinoids hair analysis just in the last few years [163-165], 
THC-COOH was included only in one study [166] but the LOQ obtained is significantly 
higher than the cut-off values and the method can be applied only for chronic use studies. 
In this project LC–MS/MS was selected as detection technique for both multi-class method 
and cannabinoids; the same column was used for the two methods. 
In multi-class method chromatographic optimization the chromatographic separation was a 
critical aspect of method development, considering the number of analytes in this study and 
the similar structures of some compounds. Different types of HPLC column were tested: 
Gemini C18 (3 μm, 100 mm×2.0 mm), Kinetex C18 (2.6 μm, 150 mm×2.1 mm); Kinetex C18 
XB (2.6 μm, 100 mm×2.1 mm); and Ascentis (2.7 μm, 150 mm×2.1 mm), all packed with 
C18. Peak separation and symmetry obtained with the Kinetex columns were higher and the 
XB was selected because of the opportunity to work at higher flow rates, thus reducing run 
time. 
Methanol as mobile phase was found to be better than acetonitrile in terms of sharpness of 
peaks, although addition of 10 % acetonitrile to methanol resulted in better selectivity. 
Addition of formic acid, at a final concentration of 7 mmol L
-1
, was necessary to obtain 
symmetrical peaks, especially for amphetamine-like compounds. 
Optimization of the gradient revealed it was essential to start the run with 100 % aqueous 
phase to avoid widening of morphine peak. As suggested in previous studies [167], to obtain 
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a better selectivity for amphetamine-like compounds a pH gradient was used by addition of 
formic acid to the aqueous phase only. Under these optimized conditions the total runtime 
(including the re-equilibration step) was 10 min. Extracted ion currents for all analytes are 
reported in Fig. II.1. 
 
 
Figure II.1. Extracted ion currents of the selected MRM transitions obtained from analysis 
of the fortified drug-free matrix created ad hoc in our laboratory 
 
For cannabinoids separation particular attention has been paid to the separation of analytes 
with common fragments and to the separation of THC-COOH from the other analytes, which 
was crucial to introduce an acquisition period for this analyte, since it is better ionized in 
negative acquisition mode contrarily to the others that are detected in positive mode.  
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Sensitivity for the analytes, particularly for THC-COOH, was properly tuned to the 
conditions given in the experimental section by direct flow injection analysis (FIA). A fixed 
amount of standards was injected using methanol as mobile phase at different flow rates, and 
the areas of the different analytes were monitored by MRM. 
Different columns, all packed with C18 particles were tested. Firstly the experiments were 
conducted on a Phenomenex Kinetex XB C18 (50 x 2.10 mm) packed with 5 μm particles. 
The mobile phase used was methanol since the signal was significantly suppressed using 
acetonitrile.  
Chromatography optimization for cannabinoids was found to be crucial also for matrix effect 
optimization. The XB C18 of 5 cm packed with 5 μm particles was optimal for analysis in 
model solution, but significant matrix effect was obtained with real samples, since the 
separation was very fast. For this reason we decided to select a longer column XB C18 (100 x 
2.10 mm) packed with smaller particles (2.6 μm) which offered increased resolution and 
efficiency.  
 
With this column a better separation of analytes and interfering compounds, still present in 
the sample despite the strong clean-up, was achieved, significantly reducing the matrix effect 
(fig II.2). 
Figure II.2. Analyte separation by means of a XB-C18 column of 100x2.10 mm (A, on 
the left) and 50x2.10 mm (B, on the right) 
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In the optimized conditions all the analytes were separated in 8 min. Extracted ion currents 
for all analytes are reported in Fig. II.3. 
 
 
 
2. External decontamination 
Before the extraction, sample washing is crucial to eliminate endogenous (fats residues, 
sweat, sebum…) or exogenous (shampoo, cosmetics…) interfering compounds. In addition 
washing step can be useful to exclude external contamination, which can lead to false 
positives. Removal of traces of analytes that may have been deposited on the hair because of 
environmental exposure and not abuse (particularly for substances that can be assumed by 
smoke) is absolutely mandatory. Cannabinoid testing may be difficult for this reason; they 
are normally assumed by smoke and can condense on hair surface; in addition they are 
extremely lipophilic compounds and incorporation into the hair matrix via environmental 
contamination is likely to occur [9]. Consequently external decontamination is important but 
only the detection of metabolites can definitively exclude passive exposure. 
On the other hand, decontamination is also required to wash only the environmental drugs 
potentially present in the sample and not the one incorporated in order to avoid false 
negatives.  
Figure III.3. Extracted ion currents of the selected MRM transitions obtained from 
analysis of a fortified hair sample 
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SoHT guidelines recommend that for washing step, the procedure should include several 
steps with both organic solvent and aqueous solutions but standardized procedures does not 
exist [71]. 
According to their ability to penetrate the keratin structure of hair [168] solvents can be 
classified as swelling and not swelling; aprotic solvents as dichloromethane and acetone 
have no extracting capacity, compared to water or methanol that are instead swelling 
solvents.  
Water (phosphate buffer) and dichloromethane were chosen for decontamination with the 
purpose of minimize all the possible polar and non-polar interfering compounds; an 
intermediate washing step was carried using isopropanol to avoid immiscible solvent 
mixing.  
For optimization of this step methanol solutions of analytes at concentration of 1 µg mL
-1
 
were sprayed on 500 mg of drug-free hair; this sample was submitted to the decontamination 
procedure to assess its efficiency. The three washing fractions were analyzed and it was 
founded that the majority of the analytes were removed by treatment with aqueous buffer 
while cannabinoids were removed by isopropanol; only traces were found in 
dichloromethane. After the decontamination step, the hair, processed and analyzed as 
described above, resulted negative for all the analytes tested.  
It has also been checked that the decontamination procedure did not actively remove the 
drugs incorporated into hair; no signal decrease was observed comparing the data obtained 
from decontaminated and un-decontaminated samples. Despite the swelling ability of water, 
the short time of contact with the keratin structure hinder the penetration of the "core" of 
hair, that, thus, remains inaccessible [169]. 
 
3. Pressurised Liquid Extraction 
The critical step in the analysis of hair is certainly extraction of the drugs from the matrix. 
Extraction is conventionally performed in two ways [168] solid liquid extraction or alkaline 
and acid digestion. The extract is then cleaned-up by SPE, SPME or LLE. 
Methanol [170-176] or methanol–acid mixtures, to improve the efficiency for basic drugs 
[177, 178], were initially proposed as extraction solvent. Acidic aqueous solutions, for 
example dilute HCl [179-182] or phosphate buffer [183, 184] have been also used, as also 
has acetonitrile, both in combination with methanol [167, 185, 186] and with acidic solutions 
[187]. The methanolic extracts were found to be rich in interfering compounds whereas the 
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aqueous extracts are cleaner; in aqueous media, however, drugs of abuse for example heroin, 
its derivative 6-MAM, and cocaine can easily undergo hydrolysis. The main disadvantage of 
solid–liquid extraction is the long contact time (16–20 h) between hair and solvent that is 
needed for good recoveries. Time can be greatly reduced, from 2 to 6 h, when the extraction 
is coupled with ultrasonic treatment [172, 174] and high temperature [170, 172-175, 177, 
184].  
Digestion by concentrated NaOH [188, 189] or enzymatic digestion [168], as well as 
extraction using HCl [190] are also very diffused. Chemical digestion requires shorter times 
(approx.30 min-1 h) but causes complete hydrolysis of many drugs; enzymatic digestion is 
prone to low recovery because of instability of the analytes at the pH and temperature 
required for optimum enzyme activity.  
Alkaline digestion is the method normally used for cannabinoids extraction. A drawback is 
that the stability of the analytes might be affected during the digestion procedure, for 
example it has been shown that CBD is not stable under the severe conditions of alkaline 
digestion [191]; other issues include large volume of organic solvent used in traditional LLE 
procedures tedious sample preparation and poor reproducibility. Also for cannabinoids 
analysis enzymatic digestion [192] and direct methanol extraction [193-195] have been 
reported but require more time, up to 5 hours.  
Novel approaches such as matrix solid phase dispersion [196] or micropulverized extraction 
[19] have recently been proposed to reduce analysis time for a number of illicit drugs. 
However, in the recent years, attention has been focused to assisted extraction techniques, to 
accelerate and improve the efficiency compared to conventional methods. Supercritical fluid 
extraction which exploits CO2 in its supercritical state [197, 198], is extremely useful but 
limited by its cost [168]. Microwave-assisted extraction has also been developed for opiates, 
cocaine and their metabolites in hair samples using dichloromethane as organic solvent 
[199]. This method revealed the potential of assisted extraction methods to reduce analysis 
time and to automate the whole process maintaining quantitatively acceptable analytical 
recoveries. 
In this work pressurised liquid extraction (PLE) was tested for the extraction of analytes 
belonging to different drug classes from hair. PLE has previously been used for extraction of 
metals from hair [41, 42] but no methods for extraction of drugs from this matrix have yet 
been reported. 
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Two PLE procedures have been developed: the first allows the extraction of 14 drugs 
belonging to the class of cocaine, amphetamines, opiates and hallucinogens, the second 
procedure is able to extract cannabinoids. These analytes have seldom been included in multi 
analytes methods [163, 165] and their analysis is generally performed separately. The 
challenges in cannabinoids hair testing arise from the low concentrations of Δ9-
tetrahydrocannabinol (THC) and of its major metabolite 11-nor-9-carboxy-THC (THC-
COOH) that is even less concentrated (fg mg
-1
) [30-32] and from their lipophilicity which 
requires special attention. 
PLE was selected in this study as extraction technique, since it allows to reduce solvent 
consumption and permit the automation of the extraction step. The extraction procedure was 
optimized testing temperature, pressure, extraction solvent and time.  
Relative recoveries, normalized to the maximum value, were evaluated on fortified hair. The 
effect of temperature on the recoveries, using water as solvent at pressure of 100 bar, is 
reported in Figure II.4.a. The highest recoveries were obtained at 150° C, which has been 
selected as extraction temperature. Considering pressure, its main role is the maintenance of 
the solvent in liquid phase and its contribution to extraction efficiency is minimal for most of 
the analytes, this was confirmed carrying out recoveries at 150° C at 70 and 100 bar (data 
not shown), so the latter was selected. The extraction solvent was later considered: the 
fortified hair was sequentially extracted with water containing increasing amounts of 
methanol; the data, normalized to the maximum amount obtained for each analyte, are 
reported in Figure II.4.b. Cannabinoids were not extracted in all the tested conditions and are 
therefore not reported in the histograms. 
a) 
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Figure II.4. (Previous page) Effect of (a)temperature, (b) extraction solvent composition, 
and (c) extraction time on the PLE relative recovery of the analytes included in the multi-
class method (data are normalized to the maximum for each analyte). The results were 
obtained from six replicates 
 
Larger amounts of analytes were extracted when the proportion of methanol was increased to 
20%, indicating that pure water was not able to extract quantitatively all the compounds 
from the hair matrix. The only analyte with decreased relative recovery in the presence of 
methanol was BZE. A reasonable explanation is that, during the procedure, COC is partially 
hydrolyzed to BZE and that a certain percentage of methanol even if small is able to 
decrease the hydrolysis reaction rate, as shown in fig 2b. No significant improvement in 
recovery was observed for amounts of methanol > 20%. The extraction time selected was 5 
min; in fact, longer times resulted in increased degradation of some analytes (Figure II.4.c). 
To allow the extraction of cannabinoids different eluents were tested since no satisfying 
results were obtained with water:methanol. Increasing the percentage of methanol up to 40% 
the co-eluting substances made the extract unsuitable for the analysis. Eluents of different 
nature, such as ethanol, hexane/ethyl acetate were also tested without good results. Different 
temperatures or extraction times did not produce better recoveries. 
Considering that it was not possible to obtain reliable results with physical means, it has 
been necessary to improve the extraction efficiency towards cannabinoids by adding a 
surfactant to the extracting solution as reported for environmental samples and plant: 
surfactants have the ability to form micelles that can solubilise different compounds, 
including very hydrophobic analytes, without the need for any strong increase in 
temperature.  
Sodium dodecyl sulfate (SDS), anionic, and Triton X-100, non-ionic, have been tested for 
this purpose (Fig II.5). 
 
 
 
 
Figure III.5. Surfactants (SDS and triton X-100) chemical strcture 
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Different concentrations of each surfactant have been added to water to find the optimal 
conditions; T and P were set at 150°C and 100 bar respectively. At the concentrations tested 
(0.25-1%), triton showed only a slight improvement in the extraction efficiency and 
produced a significant ion suppression in the following LC–MS/MS analysis despite the SPE 
clean-up. On the other hand SDS allowed to reach good results in terms of recovery 
percentage as reported in Figure II.6. These experiments have been carried out by fortifying 
blank hair samples  
 
In these experiments internal standard were added after the PLE extraction and before the 
SPE step in order to normalize the losses arising from the clean-up; only the PLE efficiency 
and not the whole procedure efficiency was evaluated at this stage. In fig. II.6 it can be 
noticed that the analytes are stable under the P and T conditions tested; SDS at 25 mM 
provides the best results for THC-COOH, while THC and CBN were better extracted with 
SDS at 50 mM. Because of the importance of THC-COOH as biomarker of cannabinoid use 
and its lower cut-off, the concentration of SDS has been set at 25 mM. We also tested the 
influence of adding methanol in the aqueous SDS solution and it was found that it had little 
influence; taking into account that a small percentage of methanol was useful in the 
following SPE step, SDS 25 mM:MeOH (90:10, v/v) was selected for the extraction.  
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Figure III.6. ASE recoveries obtained with various SDS concentrations in the eluent 
phase. 
79 
 
4. SPE clean-up optimization 
Because of the presence of potentially interfering compounds in the extracts and the 
relatively large volume (5–8 mL) obtained in the PLE, a clean-up/preconcentration step is 
necessary. SPE with reversed phase Strata X cartridges, which contain a modified styrene–
divinylbenzene sorbent, has been used for this purpose. In the case of cannabinoids extracts a 
stronger clean-up was needed to eliminate SDS which is well-known to cause problems in 
the chromatographic separation as well in the ESI ionization [200]. For this reason different 
SPE procedures were used for cannabinoids and the other analytes respectively. 
For the multi-analyte procedure, the optimization experiments were performed on fortified 
PLE drug-free hair extracts at a concentration of 100 ng mL
-1
 and recovery values, which 
include also the matrix effect (discussed later), were calculated relative to methanol standard 
solution at the same concentration. Maximum extract loading was found to be 4 mL, a 
further increase produced lower signal due to matrix effect increase. Elution was performed 
with methanol, because use of acetonitrile resulted in wider chromatographic peaks. 
Addition of formic acid to methanol improved recovery of the analytes, which possess basic 
properties. Recoveries, reported in Fig. II.7, were maximized with 10 mmol L
-1
 formic acid 
in methanol. The minimum volume of eluent, determined by analysis of subsequent fractions 
of eluate, was 500 μL. In conclusion the SPE procedure resulted in a good clean-up, high 
recovery with low standard deviations, and enrichment of approximately one order of 
magnitude (4 mL to 500 μL). 
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Figure II.7. Effect of formic acid concentration in methanol eluent on SPE recovery. The 
results were obtained from six replicates 
 
As mentioned above a stronger clean-up was needed for cannabinoids extract to remove the 
surfactant. The same SPE cartridges were used and particular attention was reserved to the 
washing step. The first experiments were carried out on model solution containing the 
selected analytes and SDS at 25 mM in water. The maximum volume of eluate (5-8 mL) 
which could be loaded into the Strata-X cartridge was initially evaluated: for the preliminary 
experiments elution was performed with 1 mL of methanol while 1 mL of water was used for 
washing. As shown in fig II.8 increasing the volume of loading solution, from 1 to 5 mL, the 
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Figure III.8. SPE recoveries obtained with different volumes of loaded SDS 
solution. 
81 
 
signal of the analytes decreased and for volume higher of 1 mL THC-COOH completely 
disappeared.  
To investigate the cause of these observations a blank sample containing SDS and submitted 
to the SPE process was analysed by the post-column infusion method (see Introduction §3) 
to evaluate if matrix effect was responsible for signal decrease.  
This experiment showed a severe suppression in correspondence to THC-COOH retention 
time; further post-column infusion tests using SDS revealed that the surfactant was 
responsible of the signal drop. Washing step was therefore optimized. In these experiments 6 
mL of SDS 25 mM in water were loaded on the cartridge and elution was performed with 
methanol; increasing percentage of methanol, up to 60% were tested in the washing solution 
(3 mL). It was found that the sorbent bed of STRATA-X cartridges allowed very strong 
washing steps, without loose of analytes as shown in fig II.9. 
 
The increase of methanol content in the washing solution has been exploited for SDS 
removal in the eluent; it can be noticed that with 3 mL of water:methanol (45:55, v/v) it was 
possible to obtain good recoveries avoiding SDS ion suppression. However in the following 
tests, especially when the eluent volume was reduced by evaporation to dryness, we have 
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Figure III.9. SPE recoveries obtained with different concentrations of methanol in the 
washing phase. 
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verified that SDS was still present; for this reason it was find optimal to add a further 
washing step with a low percentage of methanol (80:20, v/v) but a higher volume (6 mL) in 
order to avoid the analytes loss and increase SDS removal. In addition we found that the 
addition of a small quantity of formic acid was useful to reduce the losses of THC-COOH in 
the washing solution since the analyte was completely protonated in these conditions. In 
summary the washing of the cartridge is performed in two steps: 6 mL of water:methanol 
(80:20, v/v) and subsequently 3 mL of water:methanol (45:55, v/v) both containing formic 
acid 5 mM. 
Elution step was also optimized and it was found that the addition of NH3 in methanol 
allowed a better recovery of the analytes, especially THC-COOH, recoveries were not 
satisfying using less than 1 mL of eluent (fig II.10). 
 
Finally to reach the cut-off values of THC-COOH, i.e. 0.2 pg mg
-1
, drying and reconstitution 
of the eluent in a smaller volume was crucial, in order to obtain an enrichment of the 
analytes. After drying the sample was reconstituted with 50, 100, 200 and 250; too small 
volumes gave bad results because of low recoveries and high matrix effect, 200 μL was a 
good compromise and allowed to achieve an enrichment factor of 5, suitable to reach the 
requested cut-off. 
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Figure III.10. SPE recoveries obtained with different eluent phases. 
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5. Comparison of PLE extraction with traditional methods 
The evaluation of the effective ability of PLE to extract the analytes from the hair matrix is 
not easy since it is a solid matrix and traditional spiking does not allow to introduce the 
analytes inside the keratin matrix but just on its surface. On the other hand certified reference 
materials (CRM) commercially available do not contain all the drugs and metabolites 
considered in this study. For this reason an in-house fortified matrix was prepared according 
to a published procedure by NIST researchers [181], containing all the drugs of the multi-
analyte method. In the soaking procedure the ability of dimethylsulfoxide to penetrate the 
hair matrix was exploited to incorporate the drugs in the hair; a solution containing all the 
drugs was maintained in contact with the matrix for 3 weeks, assuring the incorporation of 
the analytes into the hair shaft, however the quantity of drugs effectively incorporated is not 
known. Matrices obtained with this procedure are normally used as reference materials since 
they simulate real hair samples; nevertheless there is evidence that the drug does not 
penetrate as far into the hair from soaking as it would from drug use [201]. Therefore to 
assess the performance of PLE for the extraction of cannabinoids we used positive real 
samples which can be easily obtained. 
For comparative purposes, different aliquots of real hair samples fortified by soaking and 
real positive samples (for cannabinoids) were submitted to PLE extraction and to the 
traditional extraction methods, namely NaOH digestion and HCl extraction. For the latter 
extraction approximately 50 mg of decontaminated hair fortified by soaking were heated 
with 2 mL 0.1 mol L
-1
 HCl for 24 h at 45 °C [181]. The extract was then cleaned by SPE 
(after neutralization with KOH and addition of 2 mL phosphate buffer at pH 6.0). NaOH 
digestion was performed on 50 mg of decontaminated hair, subjected to basic digestion with 
1 mL of 2.5 M NaOH at 60 °C for 25 min [166]; after cooling to room temperature, the 
solution was neutralised with formic acid. The mixture thus obtained was extracted by vortex 
mixing with 3 mL of ethyl acetate. After centrifugation the organic supernatant was 
separated, evaporated to dryness under a gentle flow of nitrogen and the residue was finally 
reconstituted in 200 μL of methanol.  
The choice of two methods was necessary because some analytes (cannabinoids…) are better 
extracted by NaOH digestion while other analytes (6-MAM, BZE…) are not stable under the 
strong alkaline conditions; contrarily all the analytes are stable under the PLE conditions. 
The results obtained demonstrate that PLE is able to extract most analytes from the hair 
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matrix similarly to traditional techniques as it is shown in table II.3 and II.4 where relative 
recoveries, normalized to maximum recovery, are shown.  
As expected, with NaOH extraction not all the tested analytes are stable. The dilute HCl 
method resulted in lower recovery compared to PLE for K and 6-MAM. The developed PLE 
method results in recovery close to the maximum for all the analytes except MOR. For the 
amphetamine-like compounds MES, K, and PCP, recovery was compared with NaOH 
digestion, whereas for opiates, cocaine and its metabolites recovery was compared with the 
dilute HCl extraction method.  
 
 
 
 
Table II.3. Comparison of relative  
recovery obtained with NaOH digestion, 
 HCl extraction and PLE. (results are  
normalized to the maximum recovery 
 for each analyte) 
 
Real comparison of results obtained for MOR and 6-MAM is not easy because of the 
possible hydrolysis of a significant fraction of 6-MAM to MOR at low pH, leading, then, to 
underestimation of the PLE extraction efficiency for MOR. This was confirmed by analysis 
of an sample of certified reference hair by HCl extraction: accuracy of 120 % was achieved 
for MOR and 32 % for 6-MAM. Accuracy near to 100% was achieved for 6-MAM and 
MOR with the PLE method. 
For the extraction of cannabinoids higher recoveries were obtained for all the analytes except 
CBN. The differences between PLE and NaOH are particularly significant for CBD which is 
Analyte Extraction recoveries (%) 
NaOH HCl PLE 
MOR - 100 50 
COD - 100 93 
6-MAM - 37 100 
MES 100 95 85 
AM 79 100 96 
MA 91 94 100 
MDA 88 95 100 
MDMA 90 92 100 
MDEA 88 95 100 
KE 100 75 89 
CO - 100 92 
NCO - 100 90 
BE - 99 100 
PCP 93 85 100 
Analyte   Extraction recoveries (%) 
NaOH PLE 
THC 88 100 
THC-COOH 68 100 
CBN 100 86 
CBD 36 100 
OH-THC 93 100 
Table II.4 Comparison of relative 
recovery obtained with NaOH 
digestion, and PLE. (results are 
normalized to the maximum recovery 
for each analyte) 
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known to be unstable under alkaline conditions and high temperatures [191]. In addition with 
PLE, recovery of THC-COOH is significantly higher and considering the extremely low 
concentrations found in real sample PLE is particularly advantageous for this analyte.  
In summary the performance of PLE for the extraction of most analytes is similar to the 
traditional techniques; for CBD and 6-MAM, PLE is convenient since these analytes are not 
stable under acid and basic conditions typical of the traditional techniques tested. In addition 
with PLE the extraction procedure is automated and the extraction time is very short 5 min 
vs 30 min and 24 h for NaOH digestion and HCl extraction respectively. 
Other procedures based on ultrasonication or incubation with phosphate buffer have recently 
been proposed [183, 202]. Under our experimental conditions, the performance of these 
methods is significantly lower than for the PLE method described and with “classical” 
NaOH digestion and HCl extraction.(from 20 to 50 % for all the analytes tested). In our 
opinion spiking of the analytes over the hair before extraction is likely to be the main reason 
for the disagreement found, confirming that the use of CRM or hair fortified by soaking is 
mandatory to evaluate extraction ability from hair. 
 
6. Validation 
6.1 Quantitation and identification 
MA-d9, MDMA-d5, BZE-d3, COC-d3, PCP-d5, THC-d3 and THC-COOH-d3 were used as 
ISs for their analogues and also for other compounds with similar chromatographic behavior 
or structure. The use, as ISs, of deuterated standards representing a class of drugs rather than 
single analytes has proved to be optimum, as reported previously [151]. Linearity was 
satisfactorily described by unweighted least-squares linear regression; reported in Table II.5 
and II.6, average determination coefficients (r
2
) were >0.99 as required by the SOFT/AAFS 
guidelines [3]. 
Different linear dynamic ranges (LDR) were investigated for the analytes because of the 
different cut-off values reported in the SoHT guidelines. For substances with no reported 
cutoff, the value given for an analogous compound was used. ULOQ for BZE and NCOC 
were set a factor of 10 lower than for cocaine because the cut off values are a factor of ten 
lower than for cocaine; this is because the values expected in real samples for cocaine 
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metabolites are lower than for the parent drug. A different LDR was investigated also for 
THC-COOH, since this analyte is found in real samples at a significantly lower 
concentration compared to the other analytes and for this reason its cut-off value is very low 
(0.2 pg mg
-1
). 
Blank samples injected between calibrators never revealed carryover phenomena; QCs were 
always within the limits of precision of the method. LODs were derived experimentally, as 
suggested by the SOFT/AAFS guidelines, for better determination of the true LOD in 
chromatographic assays [45], and are reported in Table II.5. To ensure identification of the 
analytes even at LOD levels, the latter were calculated for the MRM transition having the 
lowest S/N. LOQs were calculated similarly; for the lowest concentration of calibrator it was 
verified that an acceptable relative standard deviation (±15%) could be routinely achieved. 
The LODs and LOQs calculated enable identification and quantification of analytes to the 
cut-off values reported by SoHT, even for THC-COOH [71]. 
6.2 Matrix effect and selectivity 
Accurate assessment of matrix effects is necessary for bioanalytical methods based on LC–
MS, especially in confirmatory analysis. The proposed analytical procedure was shown to 
strongly reduce matrix effects; ion suppression always affected sensitivity by less than 14% 
except for PCP, for which sensitivity was reduced by 29 %, indicating the need to use the 
isotopically labelled PCP-d5 as internal standard. The ratio of the slopes of the calibration 
curves in solvent and hair are reported in Table II.5 and II.6. The variability of matrix effect, 
evaluated with 10 different hair samples, was <15% for all the analytes 
No interfering signals at the retention time of the analytes were recorded in analysis of drug 
free samples, demonstrating that the developed method provided good selectivity for all the 
considered analytes. The effect of melanin (as anionic polymer) on ion suppression was also 
examined. Samples of white drug-free hair, in which melanin was not present, and 
pigmented hair were processed separately; two calibration curves from the different matrices 
were created and the resulting slopes were compared with those from calibration with 
standard solutions. No statistically significant difference was observed between the 
calibration curves for white hair and pigmented hair, indicating that the amount of melanin 
did not affect the analytical response 
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Analyte IS Equation R
2
 LOD 
(pg/mg) 
LOQ 
(pg/mg) 
ME 
THC-COOH THC-COOH-d3 y= 1.42 x + 0.723 0.9921 0.08 0.20 1.11 
THC THC-d3 y= 0.0267 x + 0.017 0.9992 0.8 2.0 0.98 
CBD THC-d3 y= 0.0321 x + 0.002 0.9999 1.5 4.0 0.88 
CBN THC-d3 y=0.040 x + 0.023 0.9971 1.0 3.0 0.91 
OH-THC THC-d3 y= 0.013 x + 0.0132 0.9923 2.0 5.0 0.96 
   Table II.5. Regression data, LODs, LOQs and ME (cannabinoids). 
 
Table II.6. Regression data, LODs, LOQs and ME (multi-class method). 
 
6.3 Accuracy and precision 
Accuracy and precision were measured at two concentration values using fortified hair 
samples and resulted always within the limits of 15%. In addition, to have a better 
assessment of accuracy and precision CRM, samples prepared by soaking and real samples 
were analyzed. 
Accuracy, measured using the CRM, ranged from 90 to 111 % except for MDEA, which was 
slightly lower (88 %). For substances not present in the CRM, accuracy reported in table II.7 
is the one obtained by spiking over the hair and is close to 100 %, the lowest value being 85 
% for MES. Intraday and intermediate reproducibility, expressed as RSD, were constantly 
≤13 %; the only values exceeding 10 % were recorded for PCP and MES. The values are 
reported in table II.8 and II.9.  
  
ANALYTE IS Equation r
2
 LOD 
(pg/mg) 
LOQ 
(pg/mg) 
ME
a 
 
MOR MOR-d3 y = 0.0247 x + 0.0130 0.9997 7.6 24 0.90 
COD MOR-d3 y = 0.184 x + 0.0417 0.9995 9.4 32 0.93 
6-MAM MOR-d3 y = 0.0031 x - 0.0005 0.9960 8.4 28 0.99 
MES MA-d9 y = 0.0307 x - 0.0456 0.9996 7.4 26 0.95 
AMP MA-d9 y = 0.0297 x + 0.0632 0.9982 9.0 30 0.92 
MAMP MA-d9 y = 0.0429 x - 0.0018 0.9996 2.2 8.6 0.98 
MDA MDMA-d5 y = 0.0191 x - 0.0338 0.9979 7.0 22 0.92 
MDMA MDMA-d5 y = 0.0253 x -0.0132 0.9963 3.0 10.6 0.97 
MDEA MDMA-d5 y = 0.0375 x - 0.0411 0.9984 2.0 9.0 0.86 
K PCP-d5 y = 0.1249 x - 0.1425 0.9968 5.0 16.0 0.93 
COC CO-d3 y = 0.2524 x + 2.1814 0.9994 1.0 3.6 0.87 
NCOC CO-d3 y = 0.1610 x - 0.0299 0.9994 1.8 6.0 0.87 
BZE BE-d3 y = 0.0994 x + 0.0061 0.9992 2.0 7.0 0.87 
PCP PCP-d5 y = 0.1557 x + 0.3351 0.9996 3.0 4.8 0.71 
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                  Table II.8. Intraday and interday precision at 
       two concentrations 
 
 
 
 
 
 
 
Analyte Calculated 
concentration 
(ng/mg) 
Intra 
RSD 
(%) 
Inter 
RSD 
(%) 
MOR 0.11 6 8 
0.19 4 6 
COD 0.042 7 6 
0.097 5 7 
6ACM 0.070 7 8 
0.037 6 7 
MES 0.055 9 8 
0.14 7 11 
AM 0.15 7 6 
0.31 4 4 
MA 0.40 5 7 
0.83 5 4 
MDA 0.20 8 7 
0.43 5 7 
MDMA 0.38 5 4 
0.78 3 5 
MDEA 0.11 5 8 
0.23 6 9 
KE 1.73 4 3 
3.54 3 5 
CO 0.18 5 6 
0.34 5 8 
NCO 0.097 5 7 
0.24 5 6 
BE 0.062 6 5 
0.15 5 7 
PCP 0.019 12 13 
0.037 10 12 
 
Analyte 
Accuracy 
(%) 
MOR 105 
COD† 95 
6-MAM 96 
MES† 85 
AMP 103 
MAMP 111 
MDA 101 
MDMA 103 
MDEA 88 
K† 91 
COC 100 
NCOC† 90 
BZE 92 
PCP†  103 
THC 90 
CBN 101 
CBD 88 
Table II.7. Accuracy, 
calculated for analysis of 
a CRM. For substances 
not present in the CRM 
(†), A% was calculated 
on a sample obtained by 
spiking 
Analyte Conc 
(pg/mg)  
Intra 
RSD (%)  
Inter 
RSD (%)  
Accuracy 
(%)  
THC-COOH 0.2 11 12 89 
10 8 7 91 
THC 5 7 8 91 
200 5 9 95 
CBD 5 9 11 104 
200 3 5 109 
CBN 5 8 7 101 
200 9 10 99 
OH-THC 5 12 11 110 
200 9 9 112 
Table II.9. Accuracy and precision data for cannabinoids at 
two concentration levels 
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6.4 Stability 
Good stability of the substances in hair is already well known and is an asset of hair testing 
for drugs [5]; for this reason stability tests were conducted on working standard solutions 
and processed samples. In the long term stability experiments the intensity of the signal from 
the MRM transitions was not significantly different for all the analytes, and no significant 
alteration was recorded in short term stability, when the solution was kept at −20 °C, during 
inter-day assays. The analytes are not affected by repeated freeze–thaw cycles: calculated 
concentrations of stored and freshly prepared samples were within the intermediate 
reproducibility values of the method. Storage of samples at −20 °C was therefore justified. 
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Part III 
NPS 
Extension of the analytical targets 
 
Screening of methylenedioxyamphetamine and 
piperazine-derived designer drugs in urine using 
neutral loss and precursor ion scan 
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EXPERIMENTAL  
1. Chemical and reagents  
1-phenyl-piperazine (1-PP), 1-(3-methoxyphenyl)-piperazine (3-MeOPP), 1-(4-
triﬂuoromethylphenyl)-piperazine (4-TFMPP), 1-(2-methoxyphenyl)-piperazine (2-MeOPP), 
1-(4-ﬂuorophenyl)-piperazine (4-FPP), 4-MeOPP were purchased from Sigma Aldrich (St. 
Louise, MO,USA); 1-(4-chlorophenyl)-piperazine (pCPP), MDBP, 2-
(3,4methylenedioxyphenyl)-piperazine (2-MDPP), 1-(2-ﬂuorophenyl)piperazine (2-FPP), 1-
(2-phenylethyl)-piperazine (1-PEP) were obtained from Alfa Aesar (Karlsruhe, Germany); 
(+)-N-propyl-3,4methylendioxyamphetamine (MDPA), N,N-Di[1-(3,4-
methylendioxyphenyl)-2-propyl]amine (Bis-MDA) were purchased from LGC standards 
(Teddington, UK) while MDA, MDMA and 3,4-methylenedioxy-N-ethylamphetamine 
(MDEA) have been obtained from SALARS srl (Como, Italy). Acetonitrile and other 
organic solvents were of chromatography grade from Carlo Erba (Milano, Italy); water was 
puriﬁed using a milliQ system from Millipore (Bedford, MA USA); formic acid and 
ammonium acetate 98% were obtained from Sigma Aldrich (Milano, Italy).  
Stock solutions were prepared by dissolving or diluting each standard in the appropriate 
amount of methanol in order to obtain individual stock solutions at 1000 mg ml
-1
. The 
individual stock solutions of piperazines and methylendioxy-derived compounds were then, 
respectively, pooled together to obtain 10 mg ml
-1
 solutions in methanol, which was further 
diluted to obtain standard stock solutions containing 1 and 0.1 mg ml
-1
 of each compound.  
All the stock solutions were stored at -20 ° C. 
 
2. LC–MS/MS analysis  
Methylenedioxyamphetamine-and piperazine-derived designer drugs analysis was performed 
by LC–MS/MS. The HPLC equipment consists of a Perkin Elmer (Norwalk, CT, USA) 
Series 200 Micro-LC Pump with autosampler. A PE-Sciex API 2000 (Toronto, ON, Canada) 
triple quadrupole mass spectrometer was used for detection.  
The analytes were separated using a Gemini C18 column (10 cm x 2.0 mm ID) from 
Phenomenex (Torrance, CA, USA) packed with particles of 3.0 mm, equipped with a 
security Guard Ultra Cartridge. The mobile phases were: (A) acetonitrile and (B) 30 mM 
acetate buffer pH 4.5. The 0.4 ml min-1 ﬂow rate was split 1:4, so only 0.1 ml min-1 were 
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driven into the ion source. The same mobile phases with different chromatographic runs 
were carried out for the two classes of compounds. For piperazine-derived compounds, the 
gradient elution was as follows: increase of the organic phase from 0 to 15% in 13 min and 
linearly to 65% in the following 2.5 min. Then A was rapidly brought to 100% in 0.1 min, 
and after 2 min, the column was led to the original ratio within 3 min to enable its 
equilibration. For methylendioxyderived substances, the organic phase was initially 
increased from 10 to 30% in 5 min and linearly to 100% in the following 2.5 min. This ratio 
was maintained for 4 min, and the column was led to the initial conditions within 3 min.  
All the analytes were detected in positive ionization with a capillary voltage of 5500 V for 
methylenedioxyamphetamines and 2500 V for piperazines, nebulizer gas (air) at 20 psi for 
piperazine and 35 psi for methylendioxy-derived compounds, the turbo gas (nitrogen) at 70 
psi and 200°C. All other voltages, including declustering potential (DP), focusing potential 
(FP), entrance potential (EP), collision energy (CE) and cell exit potential (CXP) were 
optimized to provide maximum signal intensity.  
Data collection and elaboration were performed by means of Analyst 1.4 software (PE 
Sciex). Precursor ion scan and neutral loss scan modes were used for the screening of the 
drugs in human urine. For piperazines, three different experiments were selected: precursor 
ion scan of m/z 44 (CE 45 V; CXP 6 V) and neutral loss scan of m/z 43 (CE29V; 
CXP10V)and m/z 86 (CE 30 V; CXP 8 V). For this class of compounds, DP, FP and EP 
were set, respectively, at 20, 400 and 9 V. For methylendioxyderived compounds m/z 163 
(CE 15 V; CXP 8 V), 135 (CE 25 V; CXP 8 V) and 133 (CE 25 V;CXP 8 V) were selected 
in precursor ion scan mode; DP, FP and EP were set, respectively, at 10, 400 and 9 V.  
For both classes, MRM acquisition mode has been used for quantiﬁcation purposes. The 
selected masses, together with the main HPLC/MS/MS parameters, are reported in Table 
III.1. 
3. Sample preparation  
Urine samples were collected into a polyethylene tube and 3 ml were cleaned up by solid-
phase extraction (SPE) using polymeric reversed phase cartridges Strata X 30 mg/1 ml 
(Phenomenex, Torrance, CA, U.S.A.). Cartridges, installed on Visiprep vacuum system, 
were previously conditioned with 1 ml of methanol and 1 ml of water. Following the loading 
phase, cartridges were washed with 1 ml of water–methanol (50:50 v/v) containing 2% of 
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NH4OH and after drying under full vacuum, the analytes were eluted with 0.5 ml of 10 mM 
formic acid in methanol. The elute was collected into a vial for the following analysis.  
4. Validation  
Linearity, matrix effect, precision, accuracy, limits of detection (LODs) and limits of 
quantiﬁcation (LOQs) were evaluated, for both methods, according to SOFT/AAFS 
guidelines [5] and Peters et al. [142] with a few modifications. 
4.1 Linearity, LODs and LOQs  
Calibration standards were prepared in 10 mM formic acid in methanol. The calibrators were 
prepared at six levels of concentration (each point has been injected three times), from LOQ 
to 1000 ng ml-1 for each analyte, and were acquired both in MRM and neutral loss/precursor 
ion scan modes to assess linearity using both approaches. LODs represent the smallest urine 
concentration of a compound needed to give a peak height three times the noise level of the 
background signal from a blank urine sample. According to SOFT/AAFS guidelines, LODs 
were derived experimentally (not lower than the blank plus three standard deviations) on the 
analyte MRM transition with lowest S/N analyzing blank urine samples and blank urine 
samples spiked with decreasing amount of standard solution at appropriate concentration. 
LOQs were determined similarly as the smallest concentration of a substance needed to give 
a peak height ten times the noise level of the background signal from a blank urine sample. 
LODs and LOQs for the screening method were determined similarly on the extracted ion 
current chromatogram of the best experiment (in terms of signal to noise) for each analyte 
4.2 Recovery and matrix effect  
Six urine samples were spiked with the appropriate amount of standard stock solution before 
and after the SPE to obtain a concentration of 200 ng ml
-1
. Recovery was obtained by 
comparison of the average peak area of samples spiked before (A) and after SPE (B). 
Accordingly, R (%) = A/B* 100.  
The interference of the matrix on the S/N ratio was evaluated by comparing the calibration 
curves obtained in blank urine and in 10 mM formic acid in methanol for each analyte. Ion 
suppression was given by bs/bm, where bs is the slope of the calibration curve in solvent and 
bm is the slope of the calibration curve in matrix.  
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Analyte 
Rt 
(min) 
Q1 
(amu) 
EP 
(V) 
DP 
(V) 
Q3 
(amu) 
CE 
(V) 
CXP 
(V) 
piperazine-derived 
1-PP 9.3 163.0 8 60 
120.0 30 8 
77.2 55 10 
2-FPP 10.5 181.1 70 7 
138.0 28 9 
91.0 45 10 
4-FPP 10.9 181.1 57 8 
138.0 29 8 
91.0 45 14 
1-PEP 10.9 191.3 80 8 
105.0 33 10 
76.9 65 12 
2-MeOPP 11.9 193.0 60 10 
120.0 43 8 
150.0 28 9 
3-MeOPP 10.2 193.0 110 8 
150.1 29 12 
135.2 38 7 
4-MeOPP 11.2 193.0 25 9 
150.1 28 7 
122.0 35 6 
pCPP 14.9 197.3 100 11 
154.1 29 7 
117.9 49 8 
2-MDPP 4.3 207.1 75 8 
164.1 23 8 
189.9 20 12 
MDBP 11.4 220.9 135 7 
135.0 30 7 
76.9 58 9 
4-TFMPP 15.3 231.1 90 10 
188.0 33 12 
119.1 40 10 
methylenedioxyamphetamine-derived 
MDA 3.4 180.1 18 8 
163.2 15 7 
133.0 25 9 
MDMA 3.7 194.1 18 6 
163.2 17 6 
133.0 28 7 
MDEA 4.1 208.0 18 6 
163.2 17 6 
133.0 28 7 
MDPA 4.9 222.0 140 8 
163.2 21.5 8 
133.0 32 7 
Bis-MDA 6.6 342.0 80 9 
163.2 27 8 
133.0 40 10 
 
  
Table III.1. HPLC-MS-MS parameters for selected analytes (MRM) 
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4.3 Precision, accuracy and selectivity  
Precision and accuracy were calculated at three concentration levels (20, 200 and 500 ng ml-
1) using freshly prepared calibration curves both for the screening and acquisition modes. 
The experimental precision was expressed as the relative standard deviation. Precision, 
intended as within-laboratory reproducibility, was calculated for each analyte, for three 
different days from the areas of six urine samples per day spiked before SPE.  
Accuracy was estimated from six urine samples spiked before SPE step; the concentration 
relative to the mean peak area (Cc) was calculated by the calibration curve equation and was 
compared with the theoretical concentration (Ct). Accordingly A% = Cc/Ct * 100.  
The presence of any matrix interferences at the retention time of the selected analytes was 
observed by processing and analyzing 10 blank samples both in MRM and in neutral 
loss/precursor ion scan.  
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RESULTS AND DISCUSSION  
The consumption of psychoactive is changing in the last years because of the introduction of 
several new substances on the market, which are gaining popularity [52, 203]; A well-known 
structural modiﬁcation, is represented, for instance by the introduction of a methylenedioxy 
moiety into amphetamine or methamphetamine leading to the illicit drugs 3,4-
methylenedioxyamphetamine (MDA) or 3,4-methylenedioxymethamphetamine (MDMA). 
These drugs themselves have constituted the starting point for a variety of modiﬁcations that 
were directed mainly to the aromatic rings, or, with minor extent, to the amine function and 
the alkyl chain [52], leading to ‘legal highs’ (i.e. unregulated psychoactive compounds). In 
addition to these amphetamine derivatives, piperazine derivatives represent a further class of 
new drugs of abuse that are unscheduled in many countries [204-206]. Similar to 
amphetamines, speciﬁc structural modiﬁcations have been found also for this class of 
substances [207]: 1-benzyl-piperazine (BZP), 1-(3,4-methylenedioxybenzyl)-piperazine 
(MDBP), 1-(3-triﬂuoromethylphenyl)piperazine (3-TFMPP), 1-(3chlorophenyl)piperazine 
(mCPP) or 1-(4-methoxyphenyl)piperazine (4-MeOPP) are only few examples.  
In general, minor structural changes of common drugs are sufﬁcient to bypass legal controls 
since substances have to be structurally deﬁned to be scheduled. The synthesis of new 
derivatives represents an ongoing difﬁculty for analytical toxicologists since most of these 
new drugs are not detected by established analytical methods.[208]. In fact, the lack of 
reference mass spectra in the libraries and/or the use of selected ion monitoring (SIM) or 
selected reaction monitoring targeted at classic drugs of abuse can result in a failure in the 
detection of these newer designer drugs. In addition, classic screening methods as 
immunoassays are not often suitable for detection of the amphetamine-derived and new 
piperazine-derived designer drugs [204, 209, 210] 
In this part a method for the screening of methylenedioxyamphetamine-and piperazine-
derived compounds in urine by LC–MS/MS has been presented. The substances, 
characterized by possessing common moieties, are screened using precursor ion and neutral 
loss scan mode, providing also semi-quantitative data. This kind of approach was previously 
successful in the determination of different groups of compounds [211-214] and their 
potentiality for the detection of homologous unknown compounds was also demonstrated 
[215]. The application of neutral loss and precursor ion scan acquisition modes allows the 
identiﬁcation of molecules belonging to the chemical classes of 
methylenedioxyamphetamine-and piperazinederived compounds. It is not a general unknown 
97 
 
screening, such as IDA or DDA methods, but a screening directed versus aspeciﬁc class of 
substances with deﬁned MS characteristics (i.e. a speciﬁc fragmentation pattern).  
In this respect, different methods have been proposed: both methylenedioxyamphetamine-
and piperazine-derived designer drugs can be generally detected by liquid chromatography 
(LC) or gas chromatography (GC) coupled with mass spectrometry (MS) [18, 210, 216-220]. 
These techniques are typically used as conﬁrmation methods, but the scope of applications 
has expanded to comprehensive target screenings of several compounds or groups of 
compounds simultaneously. GC–MS, particularly in the full-scan electron ionization mode, 
is the reference method for comprehensive screening and reliable library assisted 
identiﬁcation [221]. Maurer et al. developed a systematic toxicological analysis (STA) for 
the screening of piperazine and amphetamine derived compounds by GC–MS in full scan 
[209, 222-225] or SIM mode [226], which were successful for the screening of a number of 
emerging designer drugs and their metabolites.  
Several approaches have been reported on the use of LC in combination with mass 
spectrometry (LC–MS or LC–MS/MS) for STA. The application of single-stage MS for this 
purpose is rather limited; instead, LC screenings with MS–MS identiﬁcation has been 
reported more frequently[227]. Usually, MS/MS screenings consist of a survey scan to 
detect the analytes and a dependent scan for measurement of the corresponding MS–MS 
spectra; the latter are then sent to library search for identiﬁcation [228, 229]. Other 
approaches are also possible [3]; recently, some authors employed multiple reaction 
monitoring (MRM) or SIM to screen a wide range of new designer drugs[218, 230]. The 
weak point is that no matter how many compounds the procedure covers, it never constitutes 
‘general untargeted’ screening because of the selection of the precursor and fragment ions. 
For this reason, other acquisition modes in MS
2
 as precursor ion or neutral loss are 
particularly interesting. These acquisition modes are very useful for the analysis of 
molecules that possess similar fragmentation pattern, with at least an identical moiety, and 
provide useful structural information allowing anyhow lower sensitivity [231]. 
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1. Liquid chromatography 
Two different chromatographic runs were optimized for each class of compounds; however, 
the same mobile phases were selected in order to avoid dead times between the experiments. 
A reverse phase column was preferred since the method is aimed to known and unknown 
molecules, and C18 columns are suitable for a wide range of analytes. The optimal 
conditions were selected using MRM detection mode taking into consideration the 
separation, the quality and the intensity of the peaks. Various mobile phases and different 
modiﬁers were evaluated to optimize the chromatographic separation; the better results were 
obtained using acetonitrile as organic phase and 30 mM acetate buffer as aqueous phase. 
Nearly all the piperazines, including some isomers, and methylendioxyamphetamines were 
well resolved. The optimized gradients present a slow increase of the organic phase in order 
to separate the maximum number of analytes.  
 
2. SPE optimization  
The optimization of the clean-up step allowed the maximization of the extraction recoveries 
and the minimization of the ion suppression from urine endogenous compounds. Capacity, 
loading and elution volume experiments were also carried out. A Strata X polymeric 
stationary phase was selected, since it allowed the pretreatment of a wide range of 
compounds.  The best conditions were initially studied loading water samples, containing 
both piperazines and methylendioxyamphetamines at concentration of 200 ng ml
-1
. The 
addition of formic acid to methanol resulted in an increase of the recoveries, as the analytes 
possess basic properties; the highest recovery was obtained using a concentration of 10 mM 
in methanol. The best elution volume was found to be 500 ml.  
Matrix effect was assessed comparing the signals of a post-extraction spiked sample and a 
sample fortiﬁed in methanol at the same level. In the above conditions, ion suppression 
resulted signiﬁcant, highlighting the need for a careful optimization of the washing step. 
Increasing the methanol amount up to 50% in water, this matrix effect was considerably 
reduced without loss of analytes; the addition of 2% ammonium hydroxide was also very 
useful to minimize the ion suppression.  
99 
 
Loading volume was ﬁnally considered: it was possible to load up to 3 ml without matrix 
effect increase, having, thus, an enrichment factor of 6. 
3. Screening approach 
Different piperazine and methylendioxyamphetamine-derived compounds having lateral 
groups of different nature and located in various positions were selected to search for 
common fragments or neutral losses. Only a few of the molecules included in the study are 
known to be psychoactive substances (i.e. 4-MeOPP, MDBP, pFPP, MDMA, MDA, 
MDEA); however, the inclusion of a wide range of molecules belonging to the same class 
was thought to be useful to improve the ability to detect the common fragments of the two 
classes since themethod is aimed also to the screening of unknown substances. Product-ion 
spectra (PIS) of the molecules were collected at different CEs and, then, characteristic 
neutral losses and product ions were selected to set up the screening methods. The PIS 
obtained for the piperazine and methylendioxy-amphetamines derived are reported in Fig. 
III.1 (common fragments and neutral losses are highlighted on the spectra). 
 It can be noticed that the neutral loss of m/z 43 is characteristic of phenyl-piperazines 
independent of the side groups, whereas the neutral loss of m/z 86 is obtained for molecules 
where the piperazine ring is not directly bound to the aromatic ring (i.e. benzyl-piperazines). 
These characteristic losses have been already reported in previous LC–MS/MS studies for 
benzylpiperazine (177.091.1) and mCPP (197.0154.1) [230]. The MS/MS 
fragmentation patterns for the ﬁve selected methylendioxy-amphetamines also gave similar 
spectra with four major fragments (m/z 163, 135, 133 and 105). The considered substances 
only differ for substitution at the amine function; CID fragmentations for this kind of 
compounds have been extensively studied [232, 233] These common fragments are likely to 
be found for all structurally related compounds. For example, the same fragmentation 
patterns were found for OH-derivatives of MDMA and MDA that have also been sold as 
new designer drugs in some drug markets [234]; the fragment ion at m/z 135 was found in 
the fragmentation pattern of N-methyl-1-(3,4methylenedioxyphenyl)-2-butanamine [235], a 
relatively novel amphetamine-type substance. 
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Fig. III.1 Product Ion Spectra for selected analyte (CE= 30 V)s 
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On the basis of the product ions discussed above, neutral-losses and precursor-ion scans 
were selected to test the method on spiked urine. Three experiments were used for each class 
of analytes to improve the selectivity for the molecules belonging to the class; detection of 
piperazines was achieved using precursor ion at m/z 44 and neutral loss of 43 and 86, while 
detection of amphetamines was obtained scanning the precursor ions at m/z 133, 135 and 
163.  
The instrumental parameters for precursor and neutral loss have been selected in order to 
obtain the best performance in terms of sensitivity for each experiment. The critical 
parameter was the CE, which has been optimized for maximizing the signal of the selected 
fragment ion for the precursor ion scan experiments, while for maximizing the intensity of 
the complementary fragment ion for neutral loss scan. As an example for precursor ion at 44 
m/z and neutral loss at 43 m/z the collision energies, although they represent the same 
cleavage, have been set at different values.  
The detection of ‘unknown compounds’ consists of a set of precursor-neutral loss scans, 
obtained with the presented screening method. Initially, precursor ion or neutral loss series 
of experiments are carried out to detect the masses of the potential ‘unknown compounds’. 
In a subsequent phase, product-ion MS/MS spectra of their molecular ions can be acquired to 
elucidate their structures and an MRM acquisition method for semi-quantitative information 
can be built. However, we have demonstrated that is possible to obtain reliable semi-
quantitative data also in precursor ion or neutral loss scan. The TIC chromatograms reported 
in Fig. III.2 clearly show the peaks for all the considered analytes. The spectra extracted 
from each peak reveal the quasi-molecular ions which can be further used in product-ion 
scan mode to elucidate the structures of the potential unknown compounds. In addition, the 
mass of the molecular ion can be extracted from the TIC chromatogram, obtaining the XIC 
proﬁle that can be useful for semi-quantitative purposes. If needed, a conﬁrmation method 
can be developed selecting suitable MRM transitions.  
Since the screening method has been designed for urinary matrix, metabolites have also to be 
considered. Piperazine designer drugs are mainly metabolized in liver, being the phenyl-
piperazines more extensively metabolized than the benzyl-piperazines. Metabolism has been 
studied only for few piperazines: while BZP and MDBP are mainly excreted as unchanged 
parent compound, extensive metabolism has been reported for mCPP, TFMPP and MeOPP 
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[236]. For these last compounds the major metabolic reactions occur at the aromatic moiety 
(mainly hydroxylation) leaving the piperazine ring unaltered, even after glucuronidation 
reaction (phase II metabolism) [223]; for this reason, metabolites are likely to be detected by 
the proposed screening method. As regards amphetamine and related compounds, substantial 
amounts of unchanged drug are present in urine, especially in acidic urine; MDMA and 
MDEA are partially metabolized to MDA [237] 
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a. 
 
b 
Fig. III.2 Chromatograms obtained from urine sample spiked with the selected analytes 
submitted to the SPE step. XIC profiles of neutral loss and/or precursor ion scan are reported 
for piperazines (a) and methylenedioxyamphetamines (b). 
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4. Validation  
The proposed procedure uses different mass spectrometric acquisition modes to screen 
compounds belonging to two different chemical classes, leading to a qualitative and a semi-
quantitative method. As reported also by Peters et al.[42], ‘for qualitative procedures, a 
general validation guideline is currently not available’. However, they suggest that for 
qualitative methods, at least selectivity and LODs should be evaluated and that other 
parameters such as precision, recovery and robustness might also be important. In our 
validation procedure, we have veriﬁed, on the reported known compounds, the method 
performance for the following parameters: linearity, LODs and LOQs; recovery and matrix 
effect; precision, accuracy and selectivity.  
4.1 Linearity, LODs and LOQs  
Calibration standard solutions were prepared over a concentration ranging from LOQ to 
1000 ng ml-1 in 10 mM formic acid in MeOH since we have no signiﬁcant difference in 
signals between urine and solvent. Linearity data, LODs and LOQs are summarized in Table 
III.2 and III.3; data obtained by MRM acquisition and screening approach are compared in 
the same table. The r
2
 values are very similar with both approaches and always > 0.99. The 
values achieved by neutral loss scan and precursor ion scan for LODs and LOQs are up to 
one order of magnitude higher; this was expected because of the higher noise obtained by 
these two acquisition methods. In any case, the values are largely below SAMHSA cut off in 
urine for amphetamines and derivatives that range from 300 to 1000 ng ml
-1
, allowing the 
present method suitable for the designed purpose. The data summarized in Table III.2 for the 
screening approach show that the method can be also employed for semi-quantitative 
procedures.  
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Analyte Equation
 
r
2
 
 MRM NL/PREC MRM NL/PREC 
piperazine-derived 
1-PP y=177x+1.06⋅103 y=2,62⋅103x-3,26⋅103 0.9967 0.9952 
2-FPP y=146x+3.73⋅103 y=2,29⋅103x+7,01⋅104 0.9946 0.9929 
4-FPP y=214x+379 y=1,49⋅103x+1,52⋅104 0.9985 0.9966 
1-PEP y=359x+1.63⋅103 y=4,29⋅103x+4,85⋅104 0.9946 0.9933 
2-MeOPP y=86.2x+761 y=1,53⋅103x+2,98⋅104 0.9953 0.9919 
3-MeOPP y=90.3x+961 y=1,72⋅103x+3,93⋅104 0.9937 0.9929 
4-MeOPP y=147x+1.33⋅103 y=945x+596 0.9965 0.9985 
pCPP y=19.3+47.2 y=794x+1,26⋅104 0.9943 0.9933 
2-MDPP Y=66.7+83.4 y=746x-6,52⋅103 0.9963 0.9929 
MDBP 55.7+342 y=4,25⋅103x+6,06⋅104 0.9958 0.9935 
4-TFMPP 106x+762 y=1,69⋅103x-6,87⋅103 0.9976 0.9992 
methylenedioxyamphetamine-derived 
MDA y=18,8x+175 y=1,74⋅103x-5,96⋅105 0.9929 0.9924 
MDMA y=148x+2,13⋅103 y=2,5⋅103x+3,78⋅103 0.9961 0.9934 
MDEA y=170x+3,54⋅103 y=2,18⋅103x+7,37⋅104 0.9931 0.9945 
MDPA y=103x+886 y=6,45⋅103x+2,12⋅105 0.9972 0.9946 
Bis-MDA y=135x+2,05⋅103 y=135x+2,05⋅103 0.9979 0.9919 
 
 
4.2 Recovery and matrix effect  
Recoveries, reported in Table III.3 resulted always >74% for each analyte. The same SPE 
procedure has been applied for the two classes of compounds allowing the pretreatment of 
both in one step. Matrix effect, evaluated on ten different blank urine samples, was greatly 
reduced as demonstrated by the nearly negligible ion suppression (see Table III.3). This 
reduction, with no diluting of the urine sample, has been achieved since the selected SPE 
cartridges allowed the inclusion of up to 50% of methanol in the washing step. Sample 
Table III.2 Regression data, for selected analytes in MRM and NL/PREC 
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acquired in neutral loss scan and precursor ion scan modes showed ion suppression very 
similar compared to MRM acquisition mode. This was expected as matrix effect result from 
the ionization stage that is not inﬂuenced by the following acquisition mode.  
 
Analyte LOD (ng ml
-1
) LOQ (ng ml
-1
) Recoveries (%) ME 
 MRM NL/PREC MRM NL/PREC   
piperazine-derived   
1-PP 1 1,5 3 5 81 0.93 
2-FPP 1 6 3 20 88 0.86 
4-FPP 2 10 6 30 81 0.96 
1-PEP 0.2 1,5 0.6 5 86 0.81 
2-MeOPP 0.3 6 1 20 85 0.95 
3-MeOPP 0.3 3 1 10 85 0.90 
4-MeOPP 1 10 3 30 90 0.99 
pCPP 2 6 6 20 92 0.86 
2-MDPP 2 20 6 60 78 0.75 
MDBP 2 2 6 6 94 0.91 
4-TFMPP 0.2 3 0.6 10 75 0.75 
methylenedioxyamphetamine-derived   
MDA 3 30 9 100 84 0.96 
MDMA 0.3 5 1 15 87 0.98 
MDEA 0.5 10 1.5 30 82 0.92 
MDPA 0.15 1.5 0.5 5 74 0.96 
Bis-MDA 0.15 5 0.5 15 80 0.84 
  
Table III.3 LODs, LOQs, recoveries and matrix effect for selected analytes  
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4.3 Precision, accuracy and selectivity  
Precision and accuracy for the quantiﬁcation and the screening method were very different. 
The MRM method exhibits a RSD < 15% and accuracy ranging from 90 to 110% for all the 
analytes, whereas the values reported for neutral and precursor acquisition mode do not 
respect, for these parameters, the acceptance criteria for a conﬁrmation method (data not 
shown). Therefore, only semi-quantitative data can be obtained from the screening approach.  
The method was found to be selective for all tested analytes. Selectivity experiments with 
ten different urine samples revealed no interferences of matrix compounds or impurities.  
The analytes were injected both as a mixture and singularly in order to evaluate the inﬂuence 
of co-eluting compounds; no signiﬁcant effect has been detected. However, it must be 
considered that among piperazine class, some drugs or their positional isomers are also 
metabolites of therapeutic drugs and might thus result from ingestion of the latter [203]. In 
cases of doubt, the presence of the respective precursor compounds must be checked to 
avoid false response (or false positive). 
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CONCLUSIONS 
In the course of the PhD research different methods based on innovative sample preparation 
techniques or novel analytical approaches were developed for the determination of 
psychotropic substances in biological matrices by means of Liquid Chromatography – 
tandem Mass Spectrometry (LC-MS/MS).  
Multi-class drugs methods were developed for confirmatory analysis of illicit drugs in urine, 
plasma, oral fluids (OF) and hair. All these methods are simple, fast and reliable and the 
sample preparation procedures present significant advantages over the methods reported in 
the literature; methods have been validated and tested on a number of real samples. 
Usefulness and applicability of the method is guaranteed by the fact that LODs and, mostly, 
LOQs for all the analytes were largely below the cut-off values suggested as the lowest 
necessary by the specific guidelines  
A single method was developed for the analysis of 11 illicit drugs from different chemical 
classes in the biological fluids, despite the greatly different features of the three matrices 
considered. Miniaturization of Solid Phase Extraction (SPE) led to the reduction of sample 
volume needed (especially useful for plasma samples). Only 100 µL can be loaded on µ-SPE 
tips reaching anyhow sufficiently low detection limits. Versatility of the developed method, 
coupled with its performance as well as the reduced cost, makes it a valuable tool for 
laboratories involved in routine forensic analysis. 
For the first time pressurized liquid extraction (PLE) was shown to be effective for the 
extraction of drugs belonging to different classes from hair samples. Quantitative extraction 
of analyte was achieved in a short time, leading to a substantial reduction of analysis time 
compared with existing extraction techniques. Decontamination step takes into account the 
complexity of the processes of external contamination and has been proved to prevent 
positive and negative false results. Ad hoc-fortified matrix allowed to take into account the 
false conclusions that can be obtained by evaluating hair extraction performance when the 
surface of the hair is spiked with the analytes before the analytical procedure.  
Cannabinoids were analysed separately, due to their distinctive chemical characteristics. 
Their determination was focused on hair, where their analysis is particularly difficult, a 
surfactant was exploited for cannabinoids extraction leading to high recoveries. The 
determination of THC-COOH has been shown to be crucial to distinguish between passive 
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drug exposure and active consumption because this metabolite is formed exclusively within 
the body; however due to its acid nature its concentration is very low. Nevertheless 
developed procedure allowed the detection of THC-COOH at its cut-off values in hair.  
Analytical target was extended to novel psychotropic substances: an original experimental 
approach, never previously reported in literature, has been proposed for the determination of 
new designer drugs, methylenedioxyamphetamine and piperazine-derived. The qualitative 
and quantitative determination of new derivatives represent an ongoing difﬁculty for 
analytical toxicologists since most of these new drugs are not detected by established 
analytical methods.  
The presented method is aimed to the screening of known and unknown substances through 
the detection of the common fragments of the two classes: characteristic neutral losses and 
product ions were selected to set up the constant neutral-loss and precursor-ion scan of the 
two chemical classes considered. These acquisition modes utilized in MS
2
 have shown great 
potentiality for the analysis of molecules that possess similar fragmentation pattern, with at 
least an identical moiety, and provide useful structural information. The applicability of the 
screening approach was studied in blank urine spiked with selected analytes and processed 
by SPE. The ability of the screening method to provide semi-quantitative data was also 
verified. This method has demonstrated to be a potentially useful tool for the identification 
of designer drugs derived from piperazines or methylenedioxyamphetamines and can be 
applied to other drugs classes. 
This PhD research route showed that analytical methods can be developed and fully 
validated obtaining satisfactory low detection limits and forensic identification of 
psychotropic substances in biological samples without the need of special instrumentations. 
All the available tools have been exploited to find each time best strategy to solve the system 
consisting of matrix - target analytes - instrumental equipment consistently with forensic 
purposes (for example a clean-up technique appropriately optimized, the use of columns 
with superficially porous packing materials to obtain greater efficiency in LC, the use of 
various and less common acquisition modes in MS/MS). 
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